Document:

Exhibit 10.1

 

CERTAIN INFORMATION IDENTIFIED IN THIS DOCUMENT, MARKED BY BRACKETS
AND ASTERISKS (“[***]”),

HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION
S-K UNDER THE SECURITIES ACT OF 1933,

AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY
CAUSE

COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.

 

RESEARCH FUNDING AND OPTION AGREEMENT

 

This Agreement is entered
into May 12, 2020 (the “Effective Date”), by and between The Scripps Research Institute, a California nonprofit public
benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037 ("TSRI"), and Xenetic Biosciences,
Inc. ("Sponsor"), a for-profit corporation located at 40 Speen Street, Suite 102, Framingham, Massachusetts 01701, with
respect to the facts set forth below.

 

RECITALS

 

A.     TSRI is engaged
in fundamental scientific biomedical and biochemical research including research relating to methods for treatment of B cell
malignancies using personalized medicine, as more particularly described herein.

 

B.     Sponsor is engaged
in research and development of personalized CAR T therapy for the treatment of hematological cancers.

 

C.     Sponsor desires
to provide certain funding as part of TSRI’s research activities described above.

 

D.     Subject to any
non-exclusive rights of the U.S. Government, TSRI is willing to grant to Sponsor an option to acquire rights and licenses to certain
intellectual property arising from the Research Program.

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the mutual covenants and conditions outlined herein, TSRI and Sponsor hereby agree as follows:

 

1.       DEFINITIONS.

 

1.1       Affiliate.
The term "Affiliate" shall mean any entity which directly or indirectly controls, or is controlled by Sponsor. The term
"control" as used herein means (a) in the case of corporate entities, direct or indirect ownership of at least fifty
percent (50%) of the stock or shares entitled to vote for the election of directors; or (b) in the case of non-corporate entities,
direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and
policies of such non-corporate entities. Unless otherwise specified, the term Sponsor includes Affiliates.

 

1.2        Agreement
Number. This Agreement is TSRI number 2020-0140.

 

1.3       Biological
Materials. The term “Biological Materials” shall mean any Technology in the form of tangible materials together
with any progeny, mutants, or derivatives thereof developed in performance of the Research Program.

 

1.4       Calendar
Quarter. The term “Calendar Quarter” shall mean that period of three months occurring from January through March
(Quarter 1), April through June (Quarter 2), July through September (Quarter 3) and October through December (Quarter 4). For purposes
of clarity, each of Quarter 1, Quarter 2, Quarter 3 and Quarter 4 is a Calendar Quarter under this Agreement.

 

 

 

    	 	1	 

     

    

 

1.5       Confidential
Information. The term "Confidential Information" shall mean any and all proprietary information of TSRI or Sponsor,
including, trade secrets, information relating to existing or contemplated products, services, technology, designs, processes,
formulae, computer systems, computer software, research programs, algorithms and research or developments, which may be exchanged
between the parties at any time and from time to time during the term hereof. The fact that a party may have marked or identified
as confidential or proprietary any specific information shall be indicative that such party believes such information to be confidential
or proprietary, but the failure to so mark information shall not conclusively determine that such information was or was not considered
confidential information by such party. Neither Party shall modify, enhance, compile or assemble (or reverse compile or disassemble),
or reverse engineer Confidential Information of the other or anything containing or embodying such Confidential Information. Neither
Party shall use any Confidential Information of the other Party or the concepts therein for its own benefit or for the benefit
of a third party or for any purpose other than for evaluating a possible business relationship. Neither Party shall remove any
proprietary legends or notices, including copyright notices, appearing on or in the Confidential Information. Each Party shall
take appropriate action with respect to each and every person permitted access to any Confidential Information to ensure that each
person complies with the confidentiality provisions hereof. Confidential Information shall also include any information which,
given the circumstances surrounding the disclosure, would be considered confidential by the disclosing party. Information shall
not be considered confidential to the extent that it:

 

a.       Is
publicly disclosed through no fault of any party hereto, either before or after it becomes known to the receiving party; or

 

b.       Was
known to the receiving party prior to the Effective Date, which knowledge was acquired independently and not from the other party
hereto (including such party's employees); or

 

c.       Is
subsequently disclosed to the receiving party in good faith by a third party who has a right to make such disclosure; or

 

d.       Was
independently developed by or on behalf of the receiving party without use of or reference to the other party’s Confidential
Information.

 

1.6        Field.
The term "Field" shall mean treatment of a B-cell Malignancy using the Technology.

 

1.7        Joint
Technology. The term "Joint Technology" shall mean any Technology developed by individuals associated with TSRI and
Sponsor under the terms of this Agreement.

 

1.8       Patent
Rights. The term “Patent Rights” shall mean:

 

(a) U.S. patents or patent
application(s) directed to the Technology;

 

(b) Foreign counterpart
patents or patent applications claiming and entitled to the priority date of the respective patents and patent application(s) referenced
in sub-clause (a) above;

 

(c) Divisionals and continuations
of any patents or patent applications referenced in sub-clauses (a) and (b) above;

 

(d) Any claim(s) of a continuation-in-part
claiming and entitled to the priority date of the respective patents and patent application(s) referenced in sub-clause (a) above;
and

 

(e) Reissues, reexaminations,
renewals and patent term extensions of the patents referenced in sub-clauses (a) - (d) above.

 

 

 

    	 	2	 

     

    

 

1.9       Principal
Investigator. The term "Principal Investigator" shall mean Dr. Lerner, together with such replacement persons selected
in accordance with the provisions of Section 2.2 hereof.

 

1.10       Research
Program. The term "Research Program" shall mean the research program to be undertaken by TSRI under the direction
and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

 

1.11       Research
Tool. The term “Research Tool” shall mean any Technology which is designed or utilized for basic research purposes
or internal drug discovery purposes and which is not utilized to produce, or incorporated into, a product.

 

1.12       Technology.
The term "Technology" shall mean any invention, discovery, know-how, Biological Material, software, information and data,
whether patentable or not, first conceived and reduced to practice during and as a result of the performance of the Research Program.

 

1.13       Technology
Rights. The term “Technology Rights” shall mean any Technology, including TSRI Technology and Joint Technology
developed pursuant to the work conducted under this Agreement.

 

1.14       TSRI
Technology. The term "TSRI Technology" shall mean any Technology developed solely by TSRI under the principles of
what constitutes an inventor under the patent laws of the United States of America.

 

2.       CONDUCT
OF RESEARCH PROGRAM.

 

2.1       Conduct
of Research Program. TSRI hereby agrees to use diligent and reasonable efforts to perform the Research Program subject to the
provisions of this Agreement. Notwithstanding the foregoing, TSRI makes no warranties or representations regarding its ability
to achieve, nor shall it be bound to accomplish, any particular research objective or results.

 

2.2       Supervision
of Research Program. TSRI agrees that the Research Program at TSRI shall be conducted by or under the direct supervision of
the Principal Investigator. In the event that the Principal Investigator leaves TSRI, or terminates his/her involvement in the
Research Program, TSRI shall use its best efforts to find a replacement Principal Investigator for whom Sponsor provides its written
acceptance, which written acceptance shall not be unreasonably withheld. In the event that TSRI shall fail to appoint a replacement
Principal Investigator reasonably acceptable to Sponsor, Sponsor shall have a right to terminate this Agreement upon delivery to
TSRI of written notice of intent to terminate pursuant to this Section 2.2, which notice must be delivered to TSRI not less
than thirty (30) days nor more than ninety (90) days after delivery by TSRI to Sponsor of the name of the replacement Principal
Investigator.

 

2.3       Reports.
TSRI agrees that within forty-five (45) days following the last day of each Calendar Quarter during the term of this Agreement,
TSRI shall furnish Sponsor with a written report summarizing the results of the research included within the scope of the Research
Program conducted by TSRI, during the immediately preceding Calendar Quarter, including but not limited to all data, conclusions,
results, analysis, observations and a detailed description of all procedures, including all materials used for each procedure.
All such reports shall be treated as Confidential Information by Sponsor

 

2.4       Financial
and Staffing Obligations

 

(a) Contributions of Parties
to Research Program. Contributions in the form of financial support, equipment, personnel, technology and other necessary components
for the conduct of the Research Program shall be made by the parties in accordance with the terms set forth on Exhibit B.
All payments due to TSRI by Sponsor shall be payable in U.S. Dollars in quarterly installments in advance, within thirty (30) days
of the dates set forth in the following payment schedule:

 

 

 

    	 	3	 

     

    

 

	 	1st
invoice: $300,013.50 (USD)	To be submitted: Effective Date
	 	 	 
	 	2nd
invoice: $300,013.50 (USD)	To be submitted: 90 days after Effective Date
	 	 	 
	 	3rd
invoice: $300,013.50 (USD)	To be submitted: 180 days after Effective Date
	 	 	 
	 	4th
invoice: $300,013.50 (USD)	To be submitted: 270 days after Effective Date
	 	 	 
	 	5th
invoice: $300,013.50 (USD)	To be submitted: 1 year anniversary of Effective Date
	 	 	 
	 	6th
invoice: $300,013.50 (USD)	To be submitted: 450 days after Effective Date
	 	 	 
	 	7th
invoice: $300,013.50 (USD)	To be submitted: 540 days after Effective Date
	 	 	 
	 	8th
invoice: $300,013.50 (USD)	To be submitted: 630 days after Effective Date
	 	 	 
	 	9th
invoice: $299,820.50 (USD)	To be submitted: 2 year anniversary of Effective Date
	 	 	 
	 	10th
invoice: $299,820.50 (USD)	To be submitted: 810 days after Effective Date

 

All invoices shall be sent to Sponsor via e-mail
at AP@xeneticbio.com. Each invoice and payment must reference the Research Project title, Agreement Number and Principal Investigator
for purposes of identification. Payments under this Section 2.4(a) shall be sent to:

 

The Scripps Research Institute

10550 North Torrey Pines
Road, TPC-7

La Jolla, California 92037

Attn: Senior Director,
Sponsored Programs

 

TSRI shall not be obligated to perform any
of the research specified herein or to take any other action required under this Agreement if the funding is not provided as set
forth in Exhibit B and in accordance with the payment schedule as set forth in this Section 2.4(a). Furthermore, should Sponsor
fail to make the first payment to TSRI in accordance with this Section 2.4(a), TSRI shall have the right to immediately terminate
this Agreement and this Agreement shall be null and void ab initio.

 

(c) Indirect Cost Adjustment.
TSRI shall have the right to adjust the payments payable under Section 2.4(a) above to reflect changes in the indirect cost rate
negotiated between TSRI and the U.S. Government that is in effect during the quarter that the work is performed. TSRI will notify
Sponsor in writing of any change in the indirect cost rate before the effective date of such change. The corresponding direct costs
will remain fixed as specified in Exhibit B.

 

 

 

    	 	4	 

     

    

 

3.       OPTION,
LICENSE AND PROSECUTION.

 

3.1       Grant
of License . Patent Rights and Technology Rights. TSRI hereby grants to Sponsor the following:

 

(a) A license within the
Field to any Patent Rights or Technology under the terms of the License Agreement Between Opko Pharmaceuticals, LLC and TSRI with
an Effective Date of February 25, 2019 (the “License Agreement”), which was later assigned to Sponsor by Opko Pharmaceuticals,
LLC on March 1, 2019. The Patent Rights or Technology Rights licensed under this section 3.1(a) will be added to Exhibit A of the
License Agreement with a notation that the scope of the license is limited to the Field.

 

(b) an exclusive option
(the “Option”) to acquire an exclusive, worldwide license, including the right to sublicense, under TSRI’s rights
in the Technology or Patent Rights not already licensed under 3.1(a). In the event that a product, process or Biological Material
utilizes a Research Tool, such Research Tool shall be made available for Sponsor’s sole use on a non-exclusive, royalty-free,
non-transferable basis solely in connection with Sponsor’s exercise of its license rights to the Patent Rights granted hereunder.

 

(c) a non-exclusive, royalty-free,
non-transferable license, without the right to grant sublicenses, to make and use TSRI Technology solely for Sponsor’s internal
research purposes during the performance of the Research Program. Any transfer of materials to Sponsor under this Section 3.1(c)
shall require the execution of a Material Transfer Agreement.

 

3.2       Disclosure
of Technology Subject to Option. After the Principal Investigator submits an invention disclosure covering any Technology to
TSRI’s Office of Technology Development, TSRI shall disclose such Technology in writing to Sponsor (the “Technology
Disclosure”). TSRI shall use reasonable efforts to provide a Technology Disclosure that contains sufficient detail to (i) enable
both parties to determine whether or not the particular Technology is TSRI Technology or Joint Technology; and (ii) enable Sponsor
to evaluate the advisability of exercising the Option granted hereunder with respect to such Technology. All such Technology Disclosures
shall be maintained in confidence by Sponsor as Confidential Information of TSRI.

 

3.3       Option
Period. Sponsor shall have a period of ninety (90) days from receipt of the Technology Disclosure from TSRI (the “Option
Period”) within which to exercise its Option with respect to the particular Technology disclosed therein. Upon delivery of
written notice that Sponsor waives its Option, or upon the failure of Sponsor to exercise its Option in writing during the Option
Period, Sponsor shall have no further rights to the particular TSRI Technology, and TSRI may license the TSRI Technology to third
parties as it sees fit.

 

3.4       Exercise
of Option. Sponsor shall exercise its Option by delivering to TSRI a written notice within the Option Period which specifies
the particular Technology for which the Option is being exercised. Upon such notification, Sponsor and TSRI shall have a period
of one-hundred and eighty (180) days within which to negotiate a definitive license agreement. Additionally, in the event
that the Parties require additional time to negotiate the definitive agreement, the Parties shall have the option to extend the
period for negotiation on a month by month basis, with the understanding that such extension requires the mutual written consent
of both Parties, which consent shall not to be unreasonably withheld or delayed.

 

3.5       Prosecution
of Patent Rights. TSRI shall direct and control the preparation, filing and prosecution of patent applications and patents
within the Patent Rights. TSRI will provide to Sponsor a copy of any communication to be filed with a patent office anywhere in
the world and TSRI shall reasonably consider any comments provided by Sponsor related to the content of the communication. As consideration
for the Option, Sponsor shall pay all reasonable fees and costs, and any and all reasonable future fees and costs associated with
work performed by TSRI’s Office of Patent Counsel and any independent counsel engaged by TSRI related to the preparation,
filing, prosecution and maintenance of the Patent Rights. Payment shall be made within thirty (30) days after Sponsor receives
an invoice therefor. Failure of Sponsor to pay patent fees and expenses as set forth above shall immediately relieve TSRI from
its obligation to incur any further patent fees and expenses with regard to the Technology that is the subject matter of the patents
for which such fees and expenses are payable. Sponsor’s obligation to pay all patent fees and costs incurred pursuant to
this Agreement shall survive the termination or expiration of this Agreement. Both parties hereto agree that TSRI may, at its sole
discretion, utilize TSRI’s Office of Patent Counsel in lieu of or in addition to independent counsel for patent prosecution
and maintenance of patent application(s). Sponsor shall have full rights of consultation with the patent attorneys so selected
on all matters relating to patent application(s), provided that TSRI shall have the final determination in all such matters.

 

 

 

    	 	5	 

     

    

 

3.6       Joint
Technology. The parties hereby agree that in the event that the disclosed Technology is Joint Technology not in the Field and
that Sponsor either does not exercise its Option or does not sign a license agreement with TSRI, both parties shall (i) have no
further obligations to each other with respect to such Joint Technology and any Patent Rights that relate thereto; and (ii) be
free to independently license or otherwise dispose of their rights to such Joint Technology and any Patent Rights that relate thereto
on a worldwide basis without accounting to the other party.

 

4.       INTERESTS
AND RIGHTS IN INTELLECTUAL PROPERTY.

 

4.1       Title.
TSRI shall retain sole ownership and title to TSRI Technology and to all intellectual property rights related thereto. TSRI shall,
in the good faith exercise of its discretion, undertake reasonable efforts to preserve and maintain its ownership and title in
and to the TSRI Technology as TSRI deems appropriate. Ownership of and title to Joint Technology shall be vested jointly in TSRI
and Sponsor, with each owning an undivided interest therein. Ownership of Patent Rights shall follow inventorship under principles
arising under U.S. patent law.

 

4.2       Governmental
Interest. TSRI and Sponsor acknowledge that TSRI has received, and expects to continue to receive, funding from the United
States Government in support of TSRI's research activities. TSRI and Sponsor acknowledge and agree that their respective rights
and obligations pursuant to this Agreement shall be subject to the rights of the United States Government, existing and as amended,
which may arise or result from TSRI’s receipt of research support from the United States Government, including but not limited
to, 37 CFR 401, the NIH Grants Policy Statement and the NIH Guidelines for Obtaining and Disseminating Biomedical Research
Resources.

 

4.3       Reservation
of Rights. All rights that are not expressly granted under this Agreement are hereby reserved. Without limiting the foregoing,
TSRI reserves the right to use for any research or educational purposes any Patent Rights, Biological Materials, or Research Tools,
without TSRI being obligated to pay Sponsor any royalties or other compensation. In addition, TSRI reserves the right to grant
non-exclusive research and educational use licenses to other nonprofit or academic institutions to Patent Rights, Biological Materials,
or Research Tools, without the other non-profit entity being obligated to pay Sponsor any royalties or other compensation.

 

5.       CONFIDENTIALITY
AND PUBLICATION.

 

5.1 Treatment of Confidential
Information. The parties agree that during the term of this Agreement, and for a period of five (5) years after this Agreement
terminates, a party receiving Confidential Information of the other party will (a) maintain in confidence such Confidential
Information to the same extent such party maintains its own proprietary information; (b) not disclose such Confidential Information
to any third party without the prior written consent of the other party; and (c) not use such Confidential Information for
any purpose except those permitted by this Agreement.

 

If Confidential Information
is required to be disclosed by law or court order, the Party required to make such disclosure shall limit the same to the minimum
required to comply with the law or court order, and shall use reasonable efforts to attempt to seek confidential treatment for
that disclosure, and prior to making such disclosure that Party shall notify the other party, not later than ten (10) days (or
such shorter period of time as may be reasonably practicable under the circumstances) before the disclosure in order to allow that
other Party to comment and/or to obtain a protective or other order, including extensions of time and the like, with respect to
such disclosure.

 

5.2 Publications.
Sponsor acknowledges that it is the general policy of TSRI to encourage publication of research results in technical or scientific
journals; and Sponsor agrees that TSRI shall have a right to publish in accordance with its general policy. TSRI shall submit to
Sponsor copies of proposed publications which describe Technology and afford Sponsor a period of thirty (30) days to review the
publication to ascertain whether Sponsor’s Confidential Information would be disclosed by the publication. If such proposed
publication would disclose Sponsor’s Confidential Information, then upon Sponsor’s written request TSRI shall remove
such Confidential Information of Sponsor or delay publication for up to an additional thirty (30) days to allow Sponsor to protect
its Confidential Information by filing a patent application(s). Absent receipt by TSRI of any written instruction by Sponsor within
the thirty (30) day period, TSRI shall be free to publish the proposed publication.

 

 

 

    	 	6	 

     

    

 

5.3 Publicity. Except
as otherwise provided herein or required by law, no party shall originate any publication, news release or other public announcement,
written or oral, whether in the public press, stockholders' reports, or otherwise, relating to this Agreement or to the performance
hereunder without the prior written approval of the other party, which approval shall not be unreasonably withheld or delayed.
TSRI agrees that Sponsor shall have the right to make those disclosures that are legally required under the laws of the United
States of America, the State of Nevada or the State of Massachusetts for a publicly traded company on a recognized stock exchange.
Scientific publications published in accordance with Section 5.2 of this Agreement shall not be construed as publicity governed
by this Section 5.3.

 

6.       WARRANTY
AND DISCLAIMER.

 

TSRI hereby represents
and warrants that it has full right and power to enter into this Agreement. TSRI MAKES NO OTHER WARRANTIES CONCERNING THE CONDUCT
OR RESULTS OF THE RESEARCH PROGRAM, PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS, BIOLOGICAL MATERIALS OR ANY OTHER MATTER WHATSOEVER,
INCLUDING WITHOUT LIMITATION, ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT
OF THIRD PARTY RIGHTS, OR ARISING OUT OF COURSE OF CONDUCT OR TRADE CUSTOM OR USAGE, AND TSRI DISCLAIMS ALL SUCH EXPRESS OR IMPLIED
WARRANTIES. TSRI MAKES NO WARRANTY OR REPRESENTATION AS TO THE VALIDITY OR SCOPE OF PATENT RIGHTS, OR THAT ANY PRODUCT, PROCESS,
SERVICE, BIOLOGICAL MATERIAL, OR RESEARCH TOOL WILL BE FREE FROM AN INFRINGEMENT ON PATENTS OR OTHER INTELLECTUAL PROPERTY RIGHTS
OF THIRD PARTIES, OR THAT NO THIRD PARTIES ARE IN ANY WAY INFRINGING UPON ANY PATENT RIGHTS, TECHNOLOGY, RESEARCH TOOLS
OR BIOLOGICAL MATERIALS COVERED BY THIS AGREEMENT. FURTHER, TSRI HAS MADE NO INVESTIGATION AND MAKES NO REPRESENTATION THAT THE
PATENT RIGHTS, RESEARCH TOOLS OR BIOLOGICAL MATERIALS ARE SUITABLE FOR SPONSOR’S PURPOSES.

 

IN NO EVENT SHALL TSRI
BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR
LOSS OF PROFITS OR EXPECTED SAVINGS OR OTHER ECONOMIC LOSSES, OR FOR INJURY TO PERSONS OR PROPERTY) ARISING OUT OF OR IN CONNECTION
WITH THIS AGREEMENT OR ITS SUBJECT MATTER. TSRI’S AGGREGATE LIABILITY, IF ANY, FOR ALL DAMAGES OF ANY KIND RELATING TO THIS
AGREEMENT OR ITS SUBJECT MATTER SHALL NOT EXCEED THE AMOUNT PAID BY SPONSOR TO TSRI UNDER THIS AGREEMENT. THE FOREGOING EXCLUSIONS
AND LIMITATIONS SHALL APPLY TO ALL CLAIMS AND ACTIONS OF ANY KIND AND ON ANY THEORY OF LIABILITY, WHETHER BASED ON CONTRACT, TORT
(INCLUDING, BUT NOT LIMITED TO NEGLIGENCE OR STRICT LIABILITY), OR ANY OTHER GROUNDS, AND REGARDLESS OF WHETHER TSRI HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. THE PARTIES FURTHER
AGREE THAT EACH WARRANTY DISCLAIMER, EXCLUSION OF DAMAGES OR OTHER LIMITATION OF LIABILITY HEREIN IS INTENDED TO BE SEVERABLE AND
INDEPENDENT OF THE OTHER PROVISIONS SINCE THEY EACH REPRESENT SEPARATE ELEMENTS OF RISK ALLOCATION BETWEEN THE PARTIES.

 

7.       TERM
AND TERMINATION.

 

7.1       Term.
Unless terminated sooner, the initial term of this Agreement shall commence on the Effective Date and shall continue for three
(3) years.

 

7.2       Termination
by Sponsor. Sponsor may terminate this Agreement by giving thirty (30) days advance written notice of termination to TSRI.

 

7.3       Termination
Upon Non-Payment. In the event that Sponsor fails to pay to TSRI any payment within the time frame set forth in Section 2.4(a),
TSRI shall not be obligated to perform any of the research specified herein or to take any other action required under this Agreement.
Sponsor shall be provided thirty (30) days to make the payment owed after receiving written notification from TSRI of failure to
make a required payment within the time frame set forth in Section 2.4(a). If Sponsor fails to make the required payment within
the thirty (30) days following receipt of written notification from TSRI, TSRI may terminate this Agreement immediately upon such
non-payment. Termination pursuant to this Section 7.3 shall not relieve Sponsor of any liability under this Agreement.

 

 

 

    	 	7	 

     

    

 

7.4       Termination
Upon Default. Except as specified in Sections 7.3 and 7.5, the failure of a party to perform any obligation required of it
to be performed hereunder and the failure to cure within sixty (60) days after receipt of notice from the other party specifying
in reasonable detail the nature of such default, shall constitute an event of default hereunder. Upon the occurrence of an event
of default, the non-defaulting party may deliver to the defaulting party written notice of intent to terminate, such termination
to be effective upon the date set forth in such notice. Such termination rights shall be in addition to and not in substitution
for any other remedies that may be available to the non-defaulting party serving such notice against the defaulting party. Termination
pursuant to this Section 7.4 shall not relieve the defaulting party of liability and damages to the non-defaulting party for
breach of this Agreement. Waiver by any party of a single default or a succession of defaults shall not deprive such party of any
right to terminate this Agreement arising by reason of any subsequent default.

 

7.5       Termination
Upon Insolvency. This Agreement may be terminated as to any party ("Insolvent Party") by another party giving written
notice of termination to the Insolvent Party upon the filing of bankruptcy or bankruptcy of the Insolvent Party or the appointment
of a receiver of any of the Insolvent Party's assets, or the making by the Insolvent Party of any assignment for the benefit of
creditors, or the institution of any proceedings against the Insolvent Party under any bankruptcy law. Termination shall be effective
upon the date specified in this notice.

 

7.6       Effect
of Expiration or Termination

 

a. Termination Upon Default
of Sponsor. Upon the termination of this Agreement by reason of a default by Sponsor, neither party shall have any further
rights or obligations with respect to this Agreement, other than the obligation of Sponsor to make any and all final payments accrued
prior to the date of termination, the obligation of the parties to make all reports required hereunder, and except as provided
below. Upon such termination of this Agreement, the parties shall continue to abide by their non-disclosure obligations as described
in Section 5.1 and each party hereto shall fulfill any other obligations incurred prior to such termination. Any such termination
of this Agreement shall not constitute the termination of any license or any other agreements between the parties which are then
in effect except as expressly provided therein. In addition, upon such termination, Sponsor’s Option under Section 3.1 shall
be deemed automatically cancelled, and Sections 4, 6, 7 and 9 shall survive any such termination.

 

b. Expiration or Termination
upon Default of TSRI. Upon the expiration of this Agreement at its regularly scheduled expiration date, or upon a termination
of this Agreement on account of a default by TSRI, then TSRI shall make the disclosures required by Section 3.2 for TSRI Technology
conceived or reduced to practice up to the date of said expiration or termination; and Sponsor shall have the right to exercise
its Option with respect to said TSRI Technology in accordance with the schedule and procedures specified in Sections 3.3
and 3.4 above; and any non-exclusive licenses that have been granted under Section 3.1 shall survive. Additionally, each party
shall perform all other obligations up to the date of said expiration or termination; and the parties shall continue to abide by
their non-disclosure obligations described in Section 5.1; and any previously existing license agreements or other agreements
between the parties shall continue in effect. In addition, upon such expiration or termination, Sections 4, 6, 7 and 9 shall survive.

 

8.       ASSIGNMENT;
SUCCESSORS.

 

8.1       Assignment.
Any and all assignments by Sponsor of this Agreement or any rights granted hereunder without the prior written consent of TSRI
are void except for assignments to an Affiliate of Sponsor.

 

8.2       Binding
Upon Successors and Assigns. Subject to the limitations on assignment set forth herein, this Agreement shall be binding upon
and inure to the benefit of any successors in interest and assigns of TSRI and Sponsor. Any such successor to or assignee of a
party's interest shall expressly assume in writing the performance of all the terms and conditions of this Agreement to be performed
by such party and such written assumption shall be delivered to the other Party.

 

 

 

    	 	8	 

     

    

 

9.       GENERAL
PROVISIONS.

 

9.1       Independent
Contractors. The relationship between TSRI and Sponsor is that of independent contractors. TSRI and Sponsor are not joint venturers,
partners, principal and agent, master and servant, employer or employee, and have no other relationship other than independent
contracting parties. TSRI and Sponsor shall have no power to bind or obligate each other in any manner, other than as is expressly
set forth in this Agreement.

 

9.2       Dispute
Resolution. Any dispute or claim between the parties arising out of or relating to this Agreement, including without limitation
the breach thereof, shall be resolved according to the following dispute resolution procedures:

 

(a)
Such dispute shall be first addressed by the representatives of TSRI and Sponsor who have primary responsibility for managing
this Agreement.

 

(b) If
the dispute is not resolved by such representatives within fifteen (15) days after the date either party gives written notice
that such dispute exists, then the dispute shall be referred to and addressed by the senior management of each
party.

 

(c) If
such dispute is not resolved by the parties’ senior management within thirty (30) days after the date the dispute is
referred to them, then the dispute shall be submitted to mediation. The mediator shall be a retired judge or other neutral
third party mutually selected by TSRI and Sponsor who has at least ten (10) years experience in mediating or arbitrating
cases in the bio-pharmaceutical industry and regarding the same or substantially similar legal and subject matter as the
dispute between Sponsor and TSRI. If the parties are unable to agree on such mediator within twenty (20) days after they
exchange initial lists of potential mediators, a mediator with the same qualifications will be selected by the JAMS office in
State of New York, New York City (after consultation with the parties). 

 

(d) The
location of the mediation shall be in the State of New York, New York City. TSRI and Sponsor hereby irrevocably submit to the
exclusive jurisdiction and venue of the mediator mutually selected by the parties for purposes of the mediation, and to the
exclusive jurisdiction and venue of the federal and state courts located in the State of New York, New York City for any
action or proceeding regarding this Agreement in the event mediation is unsuccessful as provided in sub-clause (e) below, or
as provided in sub-clause (f) below, and waive any right to contest or otherwise object to such exclusive jurisdiction or
venue, including without limitation any claim that such exclusive venue is not a convenient forum.

 

(e) If
the dispute is not resolved through mediation, either party may refer the dispute to a court of competent jurisdiction in
State of New York, New York City.

 

(f) Notwithstanding
anything to the contrary in this Agreement, prior to or while a mediation proceeding is pending, either party has the right
to seek and obtain injunctive and other equitable relief from a court of competent jurisdiction to enforce that party’s
rights hereunder.

 

9.3       Entire
Agreement; Modification. This Agreement and all of the attached Exhibits set forth the entire agreement and understanding between
the parties as to the subject matter hereof, and supersede all prior or contemporaneous written or oral agreements. There shall
be no amendments or modifications to this Agreement, except by a written document which is signed by both parties.

 

 

 

    	 	9	 

     

    

 

9.4       New
York Law. This Agreement shall be construed and enforced in accordance with the laws of the State of New York notwithstanding
any conflicts or choice of laws provisions.

 

9.5        No
Use of Name. The use of the name "The Scripps Research Institute", "Scripps", “TSRI” or any
variation thereof in connection with the advertising, sale or performance of Products, Processes, Services, Biological Materials
or Research Tools is prohibited, unless Sponsor is provided written agreement for the use of the name.

 

9.6       Headings.
The headings for each article and section in this Agreement have been inserted for the convenience of reference only and are not
intended to limit or expand on the meaning of the language contained in the particular article or section.

 

9.7       Severability.
Should any one or more of the provisions of this Agreement be held invalid or unenforceable by a court of competent jurisdiction,
it shall be considered severed from this Agreement and shall not serve to invalidate the remaining provisions thereof. The parties
shall make a good faith effort to replace any invalid or unenforceable provision with a valid and enforceable one such that the
objectives contemplated by them when entering this Agreement may be realized.

 

9.8       No
Waiver. Any delay in enforcing a party's rights under this Agreement or any waiver as to a particular default or other matter
shall not constitute a waiver of such party's rights to the future enforcement of its rights under this Agreement, excepting only
as to an express written and signed waiver as to a particular matter for a particular period of time.

 

9.9       Notices.
Any notices required by this Agreement shall be in writing, shall specifically refer to this Agreement and shall be sent by registered
or certified airmail, postage prepaid, or by telefax, telex or cable, charges prepaid, or by overnight courier, postage prepaid,
and shall be forwarded to the respective addresses set forth below unless subsequently changed by written notice to the other party:

 

	 	FOR
TSRI:	The
Scripps Research Institute

10550 North Torrey Pines
Road, TPC-9

La Jolla, California 92037

ATTN: Alliances

	 	 	 
	 	       With a copy to:	otd@scripps.edu
	 	 	 
	 	FOR SPONSOR:	Xenetic Biosciences, Inc.

40 Speen Street, Suite 102

Framingham, Massachusetts 01701

Attn: Chief Executive Officer

	 	 	 
	 	       With a copy to:	info@xeneticbio.com

 

Notices shall be deemed delivered upon the
earlier of (i) when received; (ii) three (3) days after deposit into the U.S. mail; (iii) the date notice is sent
via telefax, telex or cable; or (iv) the day immediately following delivery to an overnight courier guaranteeing next-day
delivery (except Sunday and holidays).

 

 

 

    	 	10	 

     

    

 

9.10       Compliance
with U.S. Laws. Nothing contained in this Agreement shall require or permit TSRI or Sponsor to do any act inconsistent with
the requirements of any United States law, regulation or executive order as the same may be in effect from time to time.

 

9.11       Export
Controls. It is TSRI’s policy to remain fully in compliance at all times with all U.S. export control regulations, including
but not limited to the Export Administration Regulations; International Traffic in Arms Regulations; and embargo sanctions under
the Office of Foreign Assets Control (OFAC). All activities and/or transactions contemplated or hereby agreed to within this
Agreement shall be strictly predicated on full compliance with all U.S. and international export control regulations including
but not limited to restricted party prohibitions; export license requirements. In the event that Sponsor will be providing
export-controlled material to TSRI, Sponsor must first notify TSRI of its intention to provide this material in advance of shipment.
Further, diversion of any kind of any item provided to Sponsor contrary to U.S. laws is strictly prohibited. In the event that
such diversion occurs, TSRI shall not be held liable for any consequential liability, penalties, or enforcement actions undertaken
by a U.S. Government agency or any other party in relation to such action.

 

9.12       Indemnity.
Sponsor shall indemnify, defend (by counsel reasonably acceptable to TSRI) and hold harmless TSRI and any parent, subsidiary or
other affiliated entity of TSRI and their trustees, directors, officers, employees, scientists, agents, successors, assigns and
other representatives (collectively, the “Indemnitees”) from and against all claims, suits, actions, damages, liabilities,
losses and other expenses, including without limitation reasonable attorney’s fees, expert witness fees and costs incurred
by or asserted against the Indemnitees, whether or not a lawsuit or other proceeding is filed (collectively “Claim”),
that arise out of or relate to any allegations regarding Sponsor’s use of Technology. Sponsor shall not enter into any settlement
of such Claims that imposes any obligation on TSRI, that does not unconditionally release TSRI from all liability or that would
have an adverse effect on TSRI’s reputation or business without TSRI’s prior written consent. Notwithstanding the above,
Indemnitees, at their expense, shall have the right to retain separate independent counsel to assist in defending any such Claims.
In the event Sponsor fails to promptly indemnify and defend such Claims and/or pay Indemnitees’ expenses as provided above,
Indemnitees shall have the right to defend themselves, and in that case, Sponsor shall reimburse Indemnitees for all of their reasonable
attorney’s fees, costs and damages incurred in settling or defending such Claims within thirty (30) days of each of the Indemnitees’
written requests. This indemnity shall be a direct payment obligation and not merely a reimbursement obligation of Sponsor to Indemnitees.

 

 

 

[SIGNATURES ON FOLLOWING PAGE]

 

 

 

 

 

 

 

 

 

    	 	11	 

     

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement by their duly authorized representatives as of the date set forth above.

 

	TSRI:	SPONSOR:
	 	 
	THE SCRIPPS RESEARCH INSTITUTE	XENETIC BIOSCIENCES, INC.
	
         

        By:/s/ Nikki Alvarez

        Name: Nikki Alvarez

        Title: Director, Alliances
	
         

        By: /s/ Jeffrey F. Eisenberg

        Name: Jeffrey F. Eisenberg

        Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

EXHIBIT A: RESEARCH PROGRAM

 

Overall Period of Performance: 5/1/2020
– 10/31/2022

[***]

 

Study Introduction

 

Xenetic Biosciences is developing a CAR T platform
(termed ‘XCART’) for the treatment of certain non-Hodgkin Lymphoma (NHL) subtypes, by targeting a patient- and tumor-
specific lymphoma neoantigen, namely the unique B-cell receptor (BCR) displayed by a given malignant B-cell clone.

 

XCART will utilize a universal ‘CAR cassette’,
into which neoantigen-specific, antigen-binding domains (ABDs) can be inserted to create a patient-specific CAR. The resulting
CAR construct can then be engineered into an autologous CAR T product for treatment of the patient’s lymphoma.

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	13	 

     

    

 

EXHIBIT B: BUDGET

 

	Xenetic Biosciences, Inc. 
	Principal Investigator/Program Director (Last, First, Middle):	[***]
	 
	
        BUDGET

        May 1, 2020 – Oct, 31, 2022

	PERSONNEL (Applicant organization only)	%	YEAR 1	YEAR 2	YEAR 3
	Personnel	[***]	[***]	[***]
	 	 	 	 
	SUPPLIES  (Itemize by category)	[***]	[***]	[***]
	[***]
	TRAVEL	[***]	[***]	[***]
	[***]
	OTHER EXPENSES  (Itemize by category)	[***]	[***]	[***]
	[***]
	DIRECT COSTS	 	[***]	 	[***]	 	[***]
	INDIRECT COSTS @ [***]	 	[***]	 	[***]	 	[***]
	TOTAL COSTS	 	[***]	 	[***]	 	[***]
	GRAND TOTAL	 	[***]
	 
	 	 	 	 	 	 	 	 	 

 

 

 

    	 	14Exhibit 10.2

 

 

CERTAIN INFORMATION IDENTIFIED IN THIS DOCUMENT,
MARKED BY BRACKETS AND ASTERISKS (“[***]”),

HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10) OF REGULATION S-K UNDER THE
SECURITIES ACT OF 1933,

AS AMENDED, BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE

COMPETITIVE HARM TO THE REGISTRANT
IF PUBLICLY DISCLOSED.

 

MASTER SERVICES
AGREEMENT

 

This Master Services Agreement
(“Agreement”) is made effective June 12, 2020 between Xenetic Biosciences, Inc. a Nevada corporation having
its place of business at 40 Speen Street, Suite 102, Framingham, Massachusetts 01701 (“Sponsor”) and PJSC Pharmsynthez,
a Russian public joint stock company having an address of No134, Liter 1, Poselok Kuzmolovsky, St. Kapitolovo, Vsevolozhsky
Raion, Leningradskaya Oblast, 188663, Russia (“Pharms”). When signed by both Parties, this Agreement will set forth
the terms and conditions under which Pharms agrees to provide certain services to Sponsor as set forth herein. This Agreement shall
be effective as of the date of last signature (“Effective Date”). Individually, each of Sponsor and Pharms is a “Party”
and collectively, “Parties.”

 

Recitals:

 

A.       Sponsor
is in the business of developing, manufacturing and/or distributing pharmaceutical products, medical devices and/or biotechnology
products. Pharms is in the business of developing, manufacturing and/or distributing pharmaceutical products, medical devices and/or
biotechnology products, and in providing clinical trial services, research, and other services for the pharmaceutical, medical
device and biotechnology industries.

 

B.       Sponsor
and Pharms entered into a Sponsored Research Agreement (“SRA”) on August 12, 2019 that the Parties intend to terminate
coincident with the entry of Sponsor and Pharms into this Agreement. The SRA is attached as Exhibit C to this Agreement.

 

C.       The
Parties agree that prior to termination of the SRA, Sponsor had paid $350,000 United States Dollars (“USD”) to Pharms.
The Parties also agree that the funds paid by Sponsor will be credited against amounts due under this Agreement and shall be used
by Pharms for payment of any costs and expenses incurred by Pharms or a third party engaged by Pharms pursuant to the terms of
this Agreement.

 

D.       Sponsor
and Pharms further agree and understand that the terms, obligations and rights of this Agreement shall supercede any terms, obligations
and rights either Party previously bore under the SRA, which has now been terminated by the Parties.

 

Sponsor and Pharms desire
to enter into this Agreement to provide the terms and conditions upon which Sponsor may engage Pharms from time-to-time to provide
services for individual studies or projects by executing individual Work Orders (as defined below) specifying the details of the
services, which are generally set forth in the Program Summary attached as Exhibit A, and the related terms and conditions.

 

 

 

    	 	1	 

     

    

 

Agreement:

 

		1.0	Scope of the Agreement; Work Orders; Nature of Services; Change Orders.

 

		1.1	Scope of Agreement. As a “master” form of contract, this Agreement allows the
parties to contract for multiple projects through the issuance of multiple Work Orders (as discussed in Section 1.3 below), without
having to re-negotiate the basic terms and conditions contained herein. This Agreement covers the provision of services by Pharms
and Pharms’s corporate affiliates (see Section 1.5) and, accordingly, this Agreement represents a vehicle by which Sponsor
can efficiently contract with Pharms and its corporate affiliates for a broad range of services.

 

		1.2	Nature of Services. The services covered by this Agreement may include expert consultation,
clinical trial services, data processing, data management, clerical, project management, and other research and development services
requested by Sponsor from time-to-time and agreed to by Pharms as set forth in the relevant Work Order (collectively, the “Services”).

 

		1.3	Work Orders. The specific details of each project under this Agreement (each “Project”
or “Study”) shall be separately negotiated and specified in writing on terms and in a form acceptable to the parties
(each such writing, a “Work Order”). A sample Work Order is attached hereto as Exhibit B. Each Work Order will include,
as appropriate, the scope of work, timeline, and budget and payment schedule. Each Work Order shall be subject to all of the terms
and conditions of this Agreement, in addition to the specific details set forth in the Work Order. To the extent any terms or provisions
of a Work Order conflict with the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control,
except to the extent that the relevant Work Order expressly and specifically states an intent to supersede this Agreement on a
specific matter. All Work Orders and other exhibits hereto shall be deemed to be incorporated herein by reference. The terms and
conditions of this Agreement shall apply to all work performed on each Project, including work performed prior to the effective
date of the Project at the request of Sponsor.

 

		1.4	Change Orders. Any change in the details of a Work Order or the assumptions upon which the
Work Order is based (including, but not limited to, changes in an agreed starting date for a Project or suspension of the Project
by Sponsor) may require changes in the budget and/or timelines, and shall require a written authorization of Sponsor. The changes
and associated costs will be captured in a written amendment to the Work Order (a “Change Order”). Each Change Order
shall detail the requested changes to the applicable task, responsibility, duty, budget, timeline or other matter. The Change Order
will become effective upon the execution of the Change Order by both parties, and Pharms will be given a reasonable period of time
within which to implement the changes. Both parties agree to act in good faith and promptly when considering a Change Order requested
by the other party. Without limiting the foregoing, Sponsor agrees that it will not unreasonably withhold approval of a Change
Order, even if it involves a fixed price contract, if the proposed changes in budgets or timelines result from, among other appropriate
reasons, forces outside the reasonable control of Pharms or changes in the assumptions upon which the initial budget or timelines
were based, including, but not limited to, the assumptions set forth in the budget or timelines.

 

		1.5	Affiliates and CRO Partners. Sponsor agrees that Pharms may use the services of its CRO
partners and affiliates (“Subcontractors”) to fulfill Pharms’s obligations under this Agreement or any Work Order
and Pharms shall remain responsible for all such Services performed by its Subcontractors. To the extent that Pharms uses the services
of its CRO partners or affiliates to fulfill any obligation under this Agreement or any Work Order, Pharms shall provide a copy
of any CRO partner or affiliate agreement to Sponsor prior to entry for review and comment and Pharms shall not enter into an agreement
with a CRO partner or affiliate without first obtaining Sponsor’s written consent. Sponsor shall also be provided a copy
of the final, signed agreement entered into under this Section 1.5 with a CRO partner or affiliate. The terms, conditions and rights
in this Agreement shall be incorporated into the Work Order and such affiliate, notwithstanding the foregoing, shall be solely
responsible for the performance of the Services under such Work Order. The term “affiliate” shall mean all entities
controlling, controlled by or under common control with Pharms or Sponsor, as the case may be. The term “control” shall
mean the ability to vote more than fifty percent (50%) of the voting securities of any entity or otherwise having the ability to
direct the management and policies of an entity. Any Subcontractors utilized to perform Services will be named in the Work Order.

 

 

 

    	 	2	 

     

    

 

		2.0	Payment of Fees and Expenses; Taxes;
Currency Management; Investigator Payments.

 

		2.1	Project Budget. Sponsor will pay Pharms the reasonable fees, expenses and pass-through costs
incurred in providing the Services in accordance with the budget and payment terms contained in each Work Order. Reasonable pass-through
costs will be estimated in the budget and Sponsor shall pay the actual costs incurred.

 

		2.2	Invoices. Pharms will invoice Sponsor in accordance with the budget and payment schedule
for Pharms’s fees, and monthly for its expenses and pass-through costs incurred in performing the Services. All invoice payments
shall be made to Pharms within thirty (30) days of receipt except for prepayment, advances and investigator invoices, which are
due and payable upon receipt. All invoices shall be deemed received three (3) business days after the date postmarked if sent by
mail, on the date sent if they are sent electronically or by facsimile, and three (3) days after the date they are sent if delivered
by a reputable overnight delivery service. Expenses and pass-through costs will be supported by a detailed summary sheet. If any
portion of an invoice is disputed, then Sponsor shall pay the undisputed amounts as set forth above and the parties shall use good
faith efforts to reconcile the disputed amount as soon as practicable.

 

		2.3	Taxes. Pharms shall be responsible for paying for all taxes due that are related to any
work conducted by Pharms. To the extent that any taxes constitute a cost that is reimbursable by Sponsor under this Agreement,
such tax shall be invoiced on the invoice for the month following payment of the tax.

 

		2.4	Foreign Currency Exchange. Unless otherwise specified in the Work Order, the currency to
be used for invoice and payment will be in US Dollars (the “Contracted Currency”). If a currency referenced within
the budget ceases to become legal tender, the applicable replacement currency will be substituted for such currency for purposes
of this provision at an established conversion rate.

 

		2.4.1	Pass-Through Costs. If Pharms incurs pass-through costs in a currency other than the Contracted
Currency, then Sponsor shall reimburse Pharms for Pharms’s actual costs in the Contracted Currency based on the Oanda foreign
currency exchange rate (Oanda.com) for the applicable currencies on the last business day of the month immediately preceding the
month in which such pass-through costs are submitted.

 

		2.5	Investigator Payments. If Pharms will be paying Investigators and a site where the work
performed under this Agreement is conducted on behalf of Sponsor, the parties will agree in the relevant Work Orders as to a schedule
of the amounts to be paid to Investigators. Sponsor acknowledges and agrees that payments for Investigators’ services are
pass-through payments to third parties and are separate from payments for Pharms’s Services. Sponsor agrees that it will
not withhold Investigator payments except to the extent that it has reasonable questions about the services performed by a particular
Investigator. 

 

		2.6	Milestones. In the event that milestones shall be provided under a Work Order under this
Agreement, and such milestones shall involve one or more payments by Sponsor to Pharms, the Parties agree that a table shall be
attached to the Work Order that sets forth the milestone event that triggers the payment and the amount of the payment to be made
in USD or shares of Sponsor’s common stock. To the extent that the milestone payment is made in shares of the Sponsor, the
shares shall be priced at a cost of one and 5/100 USD/Share ($1.05 USD/share). The Parties additionally agree that the decision
whether to pay the milestone payment in cash or in shares shall be at the sole discretion of the Sponsor. Further, if the milestone
payment is provided in shares of Sponsor stock, the shares shall be issued in the name of those individuals that Pharms identifies
in writing to Sponsor prior to the issuance of the shares, subject in all respects to compliance with Section 2.7.  In the
event of any change in the number or kind of outstanding shares of the Company’s common stock by reason of a stock split,
stock dividend, recapitalization or reorganization, the number of any shares subject to issuance under this Agreement as set forth
under a Work Order shall be appropriately adjusted by the Sponsor in its sole discretion, and the decision of the Sponsor regarding
any such adjustment shall be final, binding and conclusive.

 

 

 

    	 	3	 

     

    

 

		2.7	Securities Laws. Notwithstanding any provision of this Agreement to the contrary, the
issuance of any shares under this Agreement will be subject to compliance with all applicable requirements of federal, state, or
foreign law with respect to such securities and with the requirements of any stock exchange or market system upon which the shares
may then be listed. No shares will be issued hereunder if such issuance would constitute a violation of any applicable federal,
state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which
the Stock may then be listed. In addition, no shares will be issued hereunder unless such shares may be issued in accordance with
the terms of an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities
Act”). As a condition to any issuance hereunder, the Sponsor may require Pharms, or any persons designated by Pharms to receive
any shares, to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or
regulation, including the Securities Act and the provisions of Regulation D and Regulation S promulgated thereunder, and to make
any representation or warranty with respect to such compliance as may be requested by the Sponsor.

 

		3.0	Term; Termination.

 

		3.1	Term. This Agreement shall commence on the date it has been signed by all parties and shall
continue for a period of five (5) years from the date of execution, or until terminated by either party in accordance with this
Section 3.0; provided, however, that the Agreement shall continue to apply to the extent that any Work Order previously executed
under this Agreement is still active and shall apply for the duration of the Services performed under such Work Order.

 

		3.2	Termination without Cause. Sponsor may terminate this Agreement or any Work Order without
cause at any time during the term of the Agreement on thirty (30) days’ prior written notice to Pharms.

 

		3.3	Termination for Cause. Either party may terminate this Agreement or any Work Order for material
breach, which shall include Sponsor’s non-payment to Pharms, upon thirty (30) days’ prior written notice specifying
the nature of the breach, if such breach has not been substantially cured within the thirty (30) day period following the receipt
of written notification for a material breach unless the non-breaching party agrees in writing to extend the 30-day cure period.

 

		3.4	Bankruptcy. Either party may terminate this Agreement or any Work Orders immediately upon
provision of written notice if the other party becomes insolvent or files for bankruptcy.

 

		3.5	Identification of Work Order. Any written termination notice shall identify the specific
Work Order or Work Orders that are being terminated.

 

		3.6	Payment. Sponsor shall pay Pharms for all Services performed in accordance with this Agreement
and any relevant Work Order and reimburse Pharms for all costs and expenses incurred in performing those Services, including all
non-cancelable costs incurred prior to termination but paid after the termination date, even if the parties’ original payment
schedule spreads out payments for certain services or defers payments for certain services until the end of the Study. If payments
are unit or milestone based, and the Agreement or a Work Order is terminated after costs have been incurred toward achieving portions
of one or more incomplete units or milestones, Sponsor will pay for actual work performed toward those incomplete units or milestones
up to the date of termination, in addition to paying for completed units or milestones. All costs and expenses that are included
by Pharms shall be individually documented in an invoice for reimbursement and Pharms shall provide to Sponsor any and all documentary
evidence for the cost and expense, including any and all receipts..

 

		3.7	Closeout. Upon termination of a Work Order, the parties shall promptly meet to prepare a
close-out schedule, and Pharms shall cease performing all work not necessary for the orderly close-out of the Services or required
by laws or regulations. Sponsor shall pay for all actual costs, including reasonable time as mutually agreed spent by Pharms personnel,
incurred to complete activities associated with the termination and close-out of affected Projects, including the fulfillment of
any regulatory requirements.

 

 

 

    	 	4	 

     

    

 

		4.0	Confidentiality.

 

		4.1	Confidential Information. Sponsor and its affiliates possess certain confidential and proprietary
data and information, including without limitation Sponsor Property (as defined in Section 5.1 below) (“Sponsor Confidential
Information”), and Pharms and its affiliates possess certain confidential and propriety information pertaining to its operations,
methods and pricing (“Pharms Confidential Information”) (Sponsor Confidential Information and Pharms Confidential Information,
including the terms of this Agreement and any Work Order, are each referred to herein as “Confidential Information”).
“Confidential Information” does not include information that is (i) already in the receiving party’s possession;
(ii) part of the public domain through no fault of the receiving party; (iii) received from a third party authorized to provide
it; (iv) independently developed by the receiving party; or (v) required by law to be disclosed provided each party shall notify
the other party prior to making any required disclosure.

 

		4.2	Obligations. The Confidential Information shall be used by the receiving party, its affiliates,
and their employees only for purposes of performing the receiving party’s obligations hereunder. Each party agrees that it
will not reveal, publish or otherwise disclose the Confidential Information of the other party to any third party without the prior
written consent of the disclosing party, except for the receiving party’s respective affiliates, officers, directors, representatives,
agents, employees, independent contractors, consultants, firms or outside attorneys (“Representatives”) as provided
below. The receiving party may disclose the disclosing party’s Confidential Information to its Representatives who have a
need to know such Confidential Information in connection with the Services or potential services, provided that each of the foregoing
must be subject to written confidentiality obligations covering the disclosing party’s Confidential Information to the same
or greater extent as the receiving party is obligated by this Agreement, and that the receiving party remains responsible for all
disclosures made to and by its Representatives. These obligations of confidentiality and nondisclosure shall remain in effect for
a period of five years after the completion or termination of this Agreement or the applicable Work Order, whichever is later.
Neither Party shall modify, enhance, compile or assemble (or reverse compile or disassemble), or reverse engineer Confidential
Information of the other or anything containing or embodying such Confidential Information. Neither Party shall use any Confidential
Information of the other Party or the concepts therein for its own benefit or for the benefit of a third party or for any purpose
other than for evaluating a possible business relationship. Neither Party shall remove any proprietary legends or notices, including
copyright notices, appearing on or in the Confidential Information.

 

		4.3	Return of Confidential Information. Upon termination of this Agreement or a Work Order and
request by the other party, each party will return to the other party Confidential Information that are held by that party or its
employees, agents or contractors in accordance with Section 6.2 (Record Retention) or destroy them, if permissible, following the
written request of the party that owns such Confidential Information.

 

		5.0	Ownership and Inventions; No License. 

 

		5.1	Sponsor Property.
All data and information generated or derived by Pharms as the result of Services performed by Pharms under this Agreement
and which are provided by Pharms to Sponsor as deliverables under this Agreement shall be and remain the exclusive property of
Sponsor (“Sponsor Property”). Any inventions that may evolve from the data and information delivered to Sponsor as
the result of services performed by Pharms under this Agreement shall belong to Sponsor and Pharms agrees to assign its rights
in all such inventions and/or related patents to Sponsor.

 

		5.2	No License. Neither anything contained herein, nor the delivery of any information to a
party hereto, shall be deemed to grant the receiving party any right or license under any patents or patent applications or to
any know-how, technology or inventions of the disclosing party.

 

 

 

    	 	5	 

     

    

 

		6.0	Records and Materials.

 

		6.1	Record Storage. During the term of each Work Order, Pharms shall maintain all materials,
information and all other data obtained or generated by Pharms in the course of providing the Services hereunder, including all
computerized records and files, in a secure area reasonably protected from fire, theft and destruction. For global trials, the
relevant hard copy Trial Master Files (“TMF”) will be stored in the location(s) where the work is performed. The hard
copy files throughout the Project for review or other audit purposes will not be shipped to a separate location unless specifically
requested by Sponsor. If such records are requested to be shipped, Sponsor shall have sole responsibility for the costs of shipping
the materials referred to herein, and Sponsor shall retain and be responsible for the performance of any carrier designated by
Sponsor for the shipping of materials. When parties use an electronic TMF, Pharms will only maintain the image of the wet ink signatures,
and hard copies of such documents will not be maintained.

 

		6.2	Record Retention. At the completion of the Services by Pharms, all materials, information
and all other data owned by Sponsor, regardless of the method of storage or retrieval, shall be (i) delivered to Sponsor in such
form as is then currently in the possession of Pharms or (ii) disposed of, at the direction and written request of Sponsor. Sponsor
shall pay the costs associated with any of the above options. In the event of early termination, Pharms will follow Pharms procedures
for document transfers. If the TMF is held in multiple Pharms locations, it will be consolidated and shipped to the Sponsor. Sponsor
shall have sole responsibility for the costs of shipping of the materials and data referred to herein for the carrier designated
by Pharms. Sponsor shall retain and be responsible for the costs of shipping and performance of any carrier designated by Sponsor
for the shipping of materials and data. Pharms will forward all final paper and electronic Project-related records to the Sponsor.
Email communications for Services performed by Pharms will also be provided to the Sponsor in a Personal Storage Table (.pst) file
format on optical media. It is the Sponsor’s responsibility to maintain the records per the appropriate regulations and retention
periods. After three calendar months from the date the final shipment of the TMF is sent to the Sponsor, Pharms will ensure that
the TMF documentation that was stored electronically at Pharms is purged. Pharms will not maintain duplicate Project-related records.
Notwithstanding the foregoing, Pharms, however, reserves the right to retain, at its own cost and subject to the confidentiality
provisions herein, copies of all materials and data that may be needed to satisfy regulatory requirements, for insurance purposes,
marketing application support, or to demonstrate the performance of its obligations hereunder.

 

		7.0	Relationship of the Parties.

 

		7.1	Independent Contractor.
For the purposes of this Agreement, the parties hereto are independent contractors and nothing contained in this Agreement shall
be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. Neither
party shall have the power or right to bind or obligate the other party, and neither party shall hold itself out as having such
authority.

 

		8.0	Regulatory Compliance.

 

		8.1	General. Pharms agrees that its Services will be conducted in compliance with all applicable
laws, rules and regulations and with the standard of care customary in the contract research organization industry. Sponsor agrees
that its obligations in connection with the clinical trial will be conducted in compliance with all applicable laws rules and regulation
in the clinical trial industry. Pharms’s standard operating procedures will be used in performance of the Services, unless
otherwise specifically stated in the applicable Work Order. Pharms certifies that it has not been debarred under the United States
Generic Drug Enforcement Act or any applicable law in any other country and that it will not knowingly employ any person or entity
that is so debarred to perform any Services under this Agreement. Sponsor further represents that it will cooperate with Pharms
in taking any actions that Pharms reasonably believes are necessary to comply with the regulatory obligations that have been transferred
to Pharms.

 

		8.2	Privacy. To the extent applicable, Pharms and Sponsor agree to comply with all applicable
national and international privacy laws and regulations.

 

 

 

    	 	6	 

     

    

 

		8.3	Data Protection. Pharms shall at all times abide by its privacy policies and Sponsor’s
instructions on data protection when processing personal data under this Agreement.

 

		8.4	Informed Consent Forms. Sponsor will review and approve all ICF templates and any substantive
changes required by the Investigators.

 

		9.0	Audits, Regulatory Inspections and Third Party Legal Proceedings. 

 

		9.1	Sponsor Audits. During the term of the applicable Work Order, Pharms will permit Sponsor’s
representatives (provided that (a) such representatives are not competitors of Pharms); and (b) prior to any audit Sponsor shall
procure that its non-employee representative enter into a confidentiality agreement with Pharms on terms at least as stringent
as the confidentiality terms herein) to examine or audit the work performed hereunder and the facilities at which the work is conducted
at a mutually agreeable time during regular business hours to determine that the Project assignment is being conducted in accordance
with the agreed Work Order specifications and that the facilities are adequate. Sponsor agrees that it shall not disclose to any
third party any information ascertained by Sponsor in connection with any such audit or examination, except to the extent required
by law or regulation. Pharms will not provide Third Party audit reports to the Sponsor unless it is a contracted audit in the Work
Order for the Sponsor.

 

		9.2	Regulatory Inspections. Each party acknowledges that the other party may respond independently
to any regulatory correspondence or inquiry in which such party or its affiliates is named. Pharms shall whenever possible notify
Sponsor and shall provide Sponsor the opportunity to comment on any response to such regulatory correspondence or inquiry in so
far as it directly concerns a Study or Project of Sponsor for which Pharms is providing Services, wherein, such comment shall be
reasonably considered. Sponsor shall whenever possible notify Pharms and shall provide Pharms the opportunity to comment on any
response to such regulatory correspondence or inquiry in so far as it directly concerns a Study or Project of Sponsor for which
Pharms, its affiliates, Subcontractors or Third Parties is providing Services, wherein, such comment shall be reasonably considered.
In addition, each party shall notify the other party promptly of any FDA or other governmental or regulatory inspection, inquiry
or findings concerning any Study or Project of Sponsor in which Pharms is providing Services. During any such inspection or inquiry,
the parties agree to make reasonable efforts to disclose only the information required to be disclosed.

 

		9.3	Third Party Legal Proceedings. In the event that Pharms or any of its affiliates, and its
and their employees or agents is served with or becomes subject to any subpoena, order, judgment, discovery, proceeding, enforcement
or other legal process (each, a “Legal Proceeding”) and, which Legal Proceeding seeks from Pharms disclosure of any
documents or information related to the Services, to the extent such Legal Proceeding is not related to Section 13.2 or a breach
of any term of this Agreement, then Sponsor shall bear and/or reimburse Pharms for all reasonable third party fees, costs and expenses
including reasonable attorneys’ fees associated with such Legal Proceeding.

 

		10.0	Third Parties; Investigators; Non-Solicitation.

 

		10.1	Third Party Agreements. If the applicable Work Order provides that Pharms will enter into
agreements with Investigators or any other third parties to procure goods or services for the applicable Project as a pass-through
expense to Sponsor under the applicable Work Order (each, a “Third Party” and collectively, “Third Parties”),
such Third Parties shall be independent contractors and shall not be considered the employees, agents, or subcontractors of Pharms
or Sponsor. To the extent included in the scope of work and budget in applicable Work Order, Pharms will manage a Third Party related
to the applicable Study (i.e. monitor and verify Project timeline adherence, include in team meetings to the extent applicable,
highlight and escalate performance issues, recommend corrective actions, if any, related to performance, and include progress in
status reports); with the understanding that Pharms shall be responsible for the goods or services provided by any Third Parties
that provide goods or services under this Section 10.1.

 

		10.2	Indemnification. If such Third Parties request an indemnification for loss or damage caused
by the Sponsor’s Project, then Sponsor shall negotiate any such indemnification directly with the Third Party. Pharms shall
not sign such indemnifications on Sponsor’s behalf.

 

 

 

    	 	7	 

     

    

 

		11.0	Anti-Bribery. Each party undertakes to the other party that:

 

		11.1	it will not, and will procure that each of its employees, directors, officers, affiliates, subcontractors
and agents will not, (i) offer, promise or give an advantage to another person, or (ii) request, agree to receive or accept a financial
or other advantage in violation of any anticorruption laws, rules, regulations and decrees applicable to the respective party (collectively,
“Legislation”), including the United States Foreign Corrupt Practices Act, as amended (the “FCPA”), the
United Kingdom Bribery Act 2010 (the “Bribery Act”) and any implementing legislation under the OECD Convention Against
the Bribery of Foreign Government Officials in International Business Transactions (“OECD Convention”). It is each
party’s responsibility to be familiar with, and comply with, the provisions of the applicable Legislation; and

 

		11.2	from time to time, at the reasonable request of the other party, it will confirm in writing that
it has complied with its undertakings under subsection (i) above and will provide any information reasonably requested by the other
party in support of such compliance.

 

		12.0	Limitation of Liability.

 

		12.1	Consequential Damages. Neither party, nor its affiliates, nor any of their respective directors,
officers, employees, subcontractors or agents shall have any liability (including without limitation, contract, negligence and
tort liability) for any loss of profits, opportunities or goodwill or any type of indirect, incidental, punitive, exemplary, special
or consequential damages in connection with this Agreement or any Work Order or the Services performed by Pharms.

 

		13.0	Indemnification.

 

		13.1	Sponsor Indemnity. Sponsor shall indemnify, defend and hold harmless (collectively “indemnify”)
Pharms and its affiliates, and its and their directors, officers, members, managers, employees, subcontractors and agents (each,
a “Pharms Indemnified Party”), from and against any and all losses, damages, liabilities, fines, reasonable attorney
fees, court costs, and expenses (collectively “Losses”), joint or several, resulting or arising from any third-party
claims, actions, proceedings, investigations or litigation relating to or arising from any third party claims, actions, proceedings,
investigations or litigation relating to or arising from or in connection with this Agreement, any Work Order, or the Services
contemplated herein (including, without limitation, any Losses arising from or in connection with any Study, test, device, product
or potential product to which this Agreement or any Work Order relates and any Project related services provided by Pharms at the
request of Sponsor yet prior to finalization and execution of the relevant Work Order), except to the extent such Losses are determined
to have resulted solely from the gross negligence or intentional misconduct of the Pharms Indemnified Party seeking indemnity hereunder.

 

		13.2	Pharms Indemnity. Pharms shall indemnify, defend and hold harmless (collectively “indemnify”)
Sponsor and its affiliates and their directors, officers, members, managers, subcontractors, employees and agents (“Sponsor
Indemnified Party”) from and against any and all Losses, damages, liabilities, fines, reasonable attorney fees, court costs,
and expenses, joint or several, resulting or arising from any third party claims, actions, proceedings, investigations or litigation
relating to or arising from or in connection with this Agreement, any Work Order, or the Services contemplated herein, to the extent
such Losses are determined to have resulted from the gross negligence or intentional misconduct of a Pharms Indemnified Party or
Pharms breach of this Agreement.

 

		13.3	Indemnification Procedure. A party seeking indemnification or reimbursement hereunder shall
give the other party prompt notice of any such claim or lawsuit (including a copy thereof) served upon it and shall fully cooperate
with the indemnifying party and its legal representatives in the investigation of any matter the subject of indemnification. The
party seeking indemnification shall not unreasonably withhold its approval of the settlement of any claim, liability, or action
covered by Section 13.1 or Section 13.2, as applicable, will cooperate with counsel of the indemnifying or reimbursing party, and
reserves the right to engage its own counsel to assist in the defense at the expense of the indemnifying party.

 

 

 

    	 	8	 

     

    

 

		14.0	Sponsor Cooperation; Disclosure of
Hazards.

 

		14.1	Sponsor Cooperation.
Sponsor shall forward to Pharms in a timely manner all documents, materials and information in Sponsor’s possession
or control necessary for Pharms to conduct the Services. Pharms shall not be liable to Sponsor nor be deemed to have breached this
Agreement for errors, delays or other consequences arising from Sponsor’s failure to timely provide documents, materials
or information or to otherwise cooperate with Pharms in order for Pharms to timely and properly perform its obligations, and any
such failure by Sponsor shall automatically extend any timelines affected by a time period reasonably commensurate to take into
account such failure, unless Sponsor agrees in writing to pay any additional costs that would be required to meet the original
timeline.

 

		15.0	Conflict of Agreements; No Obligation
of Exclusivity.

 

		15.1	Conflict of Agreements. Pharms represents to Sponsor that it is not a party to any agreement
which would prevent it from fulfilling its obligations under this Agreement and that during the term of this Agreement, Pharms
agrees that it will not enter into any agreement to provide services which would in any way prevent it from providing the Services
contemplated under this Agreement. Sponsor agrees that it will not enter into an agreement with a third party that would alter
or affect the regulatory obligations delegated to Pharms in any Study or Project without the written consent of Pharms, which will
not be unreasonably withheld.

 

		15.2	No Obligation of Exclusivity. Neither party shall have any obligation of exclusivity of
any nature to the other. Each party shall be free to provide services or conduct or sponsor clinical or research studies involving
other parties, so long as a party’s agreement with any such third party does not prevent it from performing its obligations
under this Agreement.

 

		16.0	Change in Law or Rules Governing Clinical Trials. In the event the U.S. Food, Drug, and
Cosmetic Act, or any rule or regulation governing any Services including without limitation any Good Clinical Practice regulation
is amended revised or revoked during the term of this Agreement, the parties will discuss the effect of such change on the Agreement
and/or on Services being provided under this Agreement and work together in good faith to implement any necessary changes to the
Services.

 

		17.0	Force Majeure. In the event
either party shall be delayed or hindered in or prevented from the performance of any act required hereunder by reasons of strike,
lockouts, labor troubles, inability to procure materials or services, lack or failure of public transportation facilities, failure
of power or restrictive government or judicial orders, or decrees, riots, insurrection, war, terrorism or acts of public enemies,
blockage or embargo, Acts of God, holiday closings or vacations in the European Union, inclement weather, epidemic, fire or other
reason or cause beyond that party’s control, then performance of such act (except for the payment of money owed) shall be
excused for the period of such delay. A party may claim relief if such circumstances exist as to its subcontractor and the delay
in performance of the subcontractor will cause or contribute to a delay in performance by the party. The party claiming relief
under this provision shall notify the other of the circumstances giving rise to its application, provide an estimate of the impact
on its performance, and take reasonable steps to remove or mitigate the impediment.

 

		18.0	Notices and Deliveries.
Any notice required or permitted to be given hereunder by either party hereunder shall be in writing and shall be deemed given
on the date received if delivered personally, by a reputable overnight delivery service, or three (3) days after the date postmarked
if sent by regular, registered or certified mail, return receipt requested, postage prepaid to the following addresses:

 

	
        If to Pharms:

         
	If to Sponsor:
	
        PJSC Pharmsynthez

        Attention: CEO

        No134,
        Liter 1, Poselok Kuzmolovsky, St. Kapitolovo, Vsevolozhsky Raion

        Leningradskaya
        Oblast, 188663
	
        Xenetic
        Biosciences, Inc.

        Attention:
        Chief Scientific Officer

        40
        Speen St., Ste. 102

        Framingham, MA 01701

        

 

 

 

    	 	9	 

     

    

 

If Sponsor delivers,
ships, or mails materials or documents to Pharms, or if Pharms delivers, ships, or mails materials or documents to Sponsor or to
third parties, then the expense and risk of loss for such deliveries, shipments, or mailings shall be borne by Sponsor. Pharms
disclaims any liability for the actions or omissions of third-party delivery services or carriers. All information transmitted
by Pharms pursuant to this Agreement will be sent by the standard transmission method selected by Pharms (telephone, facsimile,
mail, personal delivery or email). Sponsor hereby consents and authorizes Pharms to send facsimiles relating to the Services, or
relating to potential future services, to any office of Sponsor or Sponsor’s affiliates.

 

		19.0	Insurance.

 

		19.1	Pharms. For the term required under the federal and local laws where the clinical trial
is to be conducted , Pharms shall obtain insurance or ensure that its respective CRO Partners or affiliates who carry out
the work obtain insurance to cover any harm to the life and/or health of a patient that occurs as a result of a clinical trial
conducted pusuant a Statement of Work under this Agreement. Pharms shall obtain an insurance coverage or ensure that its respective
CRO Partners or affiliates who carry out the work obtain insurance that is no less than the minimum required under the federal
and local laws where the clinical trial is to be conducted and the rules of the institution where the clinical trial is conducted.
In the case where the clinical trial is conducted within the legal borders of Russia, the insurance coverage and conditions shall
comply with the requirements of Federal Law of 12.04.2010 N 61-FZ "On the Circulation of Medicines", as amended.
Pharms represents and warrants that it will use reasonable efforts to name Sponsor as an additional insured on all applicable insurance
policies, whether obtained by Pharms, a CRO Partner or an affiliate. Pharms shall provide Sponsor party with a certificate of insurance
upon request. In no event shall the obligations set out in this Section 19 in any way limit or reduce any of either party’s
other obligations under this Agreement, including, without limitation, either party’s indemnification obligations set out
in Section 13.

 

		20.0	Binding Agreement and Assignment.
This Agreement shall be binding upon and inure to the benefit of Sponsor and Pharms and their respective successors and permitted
assigns. Except as stated above in Section 1.5, neither party may assign or delegate this Agreement or any Work Order or any of
its rights or obligations thereunder to any party without the express, written consent of the other party.

 

		21.0	Project
Steering Committee. To facilitate communication between the Parties and the review of the strategic decisions under this Agreement,
the Parties shall appoint a Project Steering Committee. The Project Steering Committee shall be comprised of appropriate representatives
of both Parties, initially consisting of two (2) representatives from each of Sponsor and Pharms. Each Party shall appoint a Project
Steering team leader (and other key contacts, as necessary) to serve as principal Project Steering Committee liaisons for the Parties.
Employees of each Party who are not on the Project Steering Committee may attend meetings of the Project Steering Committee, as
required to further the efforts set forth in the Work Order. The initial team leader and Party representatives shall be identified
in each Work Order that is entered into pursuant to the terms of this Agreement.

 

			Any representative
of the Project Steering Committee may designate another individual from such representative's Party to attend a meeting of the
Project Steering Committee in his or her place. In such case, the representative shall notify the other Party's representative
in writing prior to the applicable meeting. A representative of a Project Steering Committee may be changed by a Party at any time
following written confirmation of the change to the other Party.

 

The Project Steering
Committee shall plan and manage the project and associated activities to be conducted in connection with the work set forth in
each Work Order and to facilitate communication on the project between the Parties. The Project Steering Committee shall also be
responsible for the sharing of certain data relating to the Parties’ project efforts in connection with each Work Order.

 

Modification to,
and implementation of, the work set forth in each Work Order and other day-to day clinical and development activities shall be
managed by the Project Steering Committee. The Project Steering Committee shall meet no less frequently than once a month in person,
by teleconference, web-conference or video conference as agreed upon by the Parties.

 

 

 

    	 	10	 

     

    

 

			

Notwithstanding
anything herein to the contrary, the Project Steering Committee shall operate by consensus with representatives of Sponsor having
one collective vote and representatives of Pharms having one collective vote. In the event of any disagreements between the Parties,
and the inability of the Parties to reasonably resolve the disagreements within thirty (30) days of when the dispute was presented
to the Project Steering Committee, then the dispute shall be referred to the senior management representatives of each Party. For
purposes of the Project Steering Committee, Sponsor’s senior management representative shall be its Chief Executive Officer
and Pharm’s senior management representative shall be its Chairman. If the senior management is not able to reasonably settle
the dispute, the Sponsor shall have the deciding vote. If required, the Project Steering Committee shall be responsible for discussing
in good faith and agreeing on issues relating to forecasting and contingency planning with regard to a Work Order.

 

		21.0	Choice of Law, Waiver and Enforceability. This Agreement shall be construed, governed, interpreted,
and applied in accordance with the laws of the State of Delaware, exclusive of its conflicts of law provisions. The failure to
enforce any right or provision herein shall not constitute a waiver of that right or provision. Any waiver of a breach of a provision
shall not constitute a waiver of any subsequent breach of that provision. If any provisions herein are found to be unenforceable
on the grounds that they are overly broad or in conflict with applicable laws, it is the intent of the parties that such provisions
be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and
that the remaining provisions shall not in any way be affected or impaired thereby.

 

		22.0	Survival. The rights and obligations of Sponsor and Pharms, which by intent or meaning have
validity beyond such termination (including, but not limited to, rights with respect to inventions, confidentiality, discoveries
and improvements, indemnification and liability limitations) shall survive the termination of this Agreement or any Work Order.

 

		23.0	Entire Agreement, Headings and Modification. This Agreement, together with the relevant
Work Orders, contains the entire understandings of the parties with respect to the subject matter herein, and supersedes all previous
agreements (oral and written), negotiations and discussions. The descriptive headings of the sections of this Agreement are inserted
for convenience only and shall not control or affect the meaning or construction of any provision hereof. Any modifications to
the provisions herein must be in writing and signed by the parties.

 

		24.0	Counterparts. This Agreement may be executed in any number of counterparts, each of which
when executed and delivered, shall constitute an original, but all of which together shall constitute one agreement binding on
all parties, notwithstanding that all parties are not signatories to the same counterpart. Transmission by fax or by electronic
mail of an executed counterpart of this Agreement shall be deemed to constitute due and sufficient delivery of such counterpart.
This Agreement and any Work Order, Change Order, amendment or modification may not be denied legal effect or enforceability solely
because it is in electronic form, or because an electronic signature or electronic record was used in its formation.

 

		25.0	Authority. Each party represents and warrants that it has the power and authority to enter
and perform its obligations under this Agreement without conflict with, default under, or violation of any law, regulation, or
agreement binding upon it. Each party represents and warrants that this Agreement has been duly and validly executed and delivered
by it and constitutes its legally valid and binding obligation, enforceable in accordance with its terms, except as enforcement
may be limited by law or in equity.

 

 

 

 

Remainder of page intentionally left blank;
signature follow on next page

 

 

 

    	 	11	 

     

    

 

IN WITNESS WHEREOF, this
Agreement has been executed by the parties hereto through their duly authorized officers on the date(s) set forth below.

 

 

ACKNOWLEDGED, ACCEPTED AND AGREED TO:

 

	
        PJSC Pharmsynthez
	
        Xenetic Biosciences, Inc.

	 	 
	
        By: /s/ Efim Prilezhaev
	
        By: /s/ Jeffrey F. Eisenberg

	           (signature)	           (signature)
	 	 
	
        Print Name: Efim Prilezhaev
	
        Print Name: Jeffrey F. Eisenberg

	 	 
	
        Title: CEO
	
        Title: Chief Executive Officer

	 	 
	
        Date: June 12, 2020
	
        Date: June 12, 2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	12	 

     

    

 

EXHIBIT A

PROGRAM SUMMARY

 

 

 Introduction

 

Xenetic Biosciences is developing a CAR T platform (termed
‘XCART’) for the treatment of certain non-Hodgkin Lymphoma (NHL) subtypes, by targeting a patient- and tumor- specific
lymphoma neoantigen, namely the unique B-cell receptor (BCR) displayed by a given malignant B-cell clone.

 

XCART will utilize a universal ‘CAR
cassette’, into which neoantigen-specific, antigen-binding domains (ABDs) can be inserted to create a patient-specific CAR.
The resulting CAR construct can then be engineered into an autologous CAR T product for treatment of the patient’s lymphoma.

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	13	 

     

    

 

EXHIBIT B

SAMPLE WORK ORDER

 

WORK ORDER

 

This Work Order (“Work Order”)
is between Xenetic Biosciences, Inc., 40 Speen St., Ste 102, Framingham, MA 01701 (“Sponsor”) and PJSC Pharmsynthez,
No134, Liter 1, Poselok Kuzmolovsky, St. Kapitolovo, Vsevolozhsky Raion, Leningradskaya Oblast, 188663, Russia (“Pharms”)
and relates to the Master Services Agreement dated as of June 12, 2020 (the “Agreement”), which is incorporated by
reference herein. Pursuant to the Agreement, Pharms has agreed to perform certain services in accordance with written Work Orders,
such as this one, entered into from time-to-time. This Work Order sets forth the obligations of the parties with regard to conducting
a Stage 1 study (as described in the Attachments to this Work Order) of Sponsor’s XCART technology, under a protocol (the
“Protocol”) to be prepared and agreed by the Project Steering Committee (as described below). Once the final Protocol
is prepared, such Protocol, including any amendments thereto, is incorporated herein by reference.

 

The parties hereby agree
as follows:

 

1.        Work
Order. This document constitutes a “Work Order” under the Agreement and this Work Order and the services contemplated
herein are subject to the terms and provisions of the Agreement.

 

2.       Services
and Payment of Fees and Expenses. The specific services contemplated by this Work Order (the “Services”) and the
related payment terms and obligations are set forth on the following attachments, which are incorporated herein by reference:

 

	PROJECT ASSUMPTIONS	ATTACHMENT 1
	SCOPE OF WORK/BUDGET	ATTACHMENT 2
	TIMELINE	ATTACHMENT 3
	PAYMENT SCHEDULE	ATTACHMENT 4
	MILESTONE//PAYMENTS	ATTACHMENT 5
	THIRD PARTY VENDORS	ATTACHMENT 6

 

3.       Term.
The term of this Work Order shall commence on the date of execution and shall continue until the Services described in Attachment
2 are completed, unless this Work Order is terminated in accordance with the Agreement. If the Agreement is terminated or expires,
but this Work Order is not terminated or completed, then the terms of the Agreement shall continue to apply to this Work Order
until the Work Order is either terminated or completed.

 

4.       Amendments.
No modification, amendment, or waiver of this Work Order shall be effective unless in writing and duly executed and delivered by
each party to the other.

 

5.       Standard
Operating Procedures. Pharms shall conduct the Study according to the formats and procedures set forth in Pharms’s Standard
Operating Procedures (“SOPs”).

 

6.       Third
Parties. The Third Party vendors who will be performing services on the Study are set forth in Attachment 6. Sponsor has provided
its written consent and approves such Third Party vendors listed and referred to within this Agreement.

 

 

 

 

    	 	14	 

     

    

 

7.       Project
Steering Committee Members. The initial team leader and Party representatives for the work conducted under this Work Order
are:

 

Sponsor: 1 Curtis Lockshin,
CSO; 2 Jeffrey Eisenberg, CEO

 

Pharms: 1 Dmitry Genkin,
Member & Chairman of the Board of Directors; 2 Kirill Surkov, CEO’s science advisor

 

ACKNOWLEDGED, ACCEPTED AND AGREED TO:

 

 

	
        PJSC Pharmsynthez
	
        Xenetic Biosciences, Inc.

	 	 
	
        By:_________________________
	
        By:_________________________

	           (signature)	           (signature)
	 	 
	
        Print Name: ___________________
	
        Print Name: ___________________

	 	 
	
        Title: ________________________
	
        Title: ________________________

	 	 
	
        Date: ________________________
	
        Date: ________________________

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	15	 

     

    

 

ATTACHMENT 1: PROJECT ASSUMPTIONS

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	16	 

     

    

 

ATTACHMENT 2: SCOPE OF WORK/PROJECT BUDGET

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	17	 

     

    

 

ATTACHMENT 3: TIMELINE

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	18	 

     

    

 

ATTACHMENT 4: PAYMENT SCHEDULE

 

[***]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	19	 

     

    

 

ATTACHMENT 5: MILESTONES SCHEDULE AND PAYMENTS

(Stages defined in Exhibit A –Program
Summary)

 

Table 1

 

	Milestone Event	Payment in USD	Payment in Shares
	[***]	$52,500	50,000 shares
	[***]	$472,500	450,000 shares
	[***]	$525,000	500,000 shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	20	 

     

    

 

ATTACHMENT 6: THIRD PARTY AGREEMENTS

 

 

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry
(Moscow)

 

Belarussian Research Center for Pediatric Oncology, Hematology
and Immunology

 

Institute of Bioorganic Chemistry of NASB

 

Viciebsk Regional Clinical Oncological Center

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	21	 

     

    

 

EXHIBIT C

 

SPONSORED RESEARCH AGREEMENT BETWEEN XENETIC
AND PHARMSYNTHEZ

 

SPONSORED RESEARCH AGREEMENT

 

This Sponsored Research Agreement (the "Agreement"),
is entered into and effective as of August 12, 2019 (the "Effective Date") by and between PJSC «Pharmsynthez»,
a Russian public joint stock company having an address of N2134, Liter 1, Poselok Kuzmolovsky, St. Kapitolovo, Vsevolozhsky Raion,
Leningradskaya Oblast, 188663, Russia ("Institution"), and Xenetic Biosciences, Inc. having an address of 40 Speen Street,
Ste. 102, Framingham, MA 01701 ("Sponsor"). For the purposes of this Agreement, Sponsor and Institution may each be referred
to as a "Party" and together as the "Parties."

 

WHEREAS, Sponsor desires to sponsor
a Research Project (defined below) at the Institution under a Principal Investigator selected by the Institution and approved by
the Sponsor;

 

WHEREAS, Sponsor desires
to have the Principal Investigator perform the Research Project on behalf of Sponsor, which shall relate to CAR-T Technology (the
"Purpose");

 

WHEREAS,
the research will be conducted pursuant to one or more Work Orders, which the Parties shall agree upon prior to the initiation
of the work and which shall be subject to the terms of this Agreement; and

 

WHEREAS,
Institution is willing to (a) undertake the Research Project, and (b) grant to Sponsor certain rights under terms and conditions
set forth herein.

 

ARTICLE 1: DEFINITIONS

 

1.1       "Affiliate"
means any person, corporation, company, partnership, joint venture and/or finn which controls, is controlled by or is under
common control with Sponsor. As used herein, "control" shall mean direct or indirect ownership of at least fifty percent
(50%) of the stock or shares having the right to vote for the election of directors.

 

1.2       "Budget"
means the indicative budget that shall be set forth in each Work Order and shall detail the payments to be made by Sponsor
for the conduct of the Research Project, including the amounts due, payment schedule, the location where invoices should be sent,
and the manner and location where payments should be made, with the understanding that the total budget for all work to be conducted
pursuant to this Agreement and all Work Orders entered into by the Parties shall not exceed three hundred fifty thousand United
States Dollars ($350,000 USD).

 

1.3       "Invention"
shall mean any discovery, improvement or invention, whether patentable or not, developed, conceived, or reduced to practice
during performance of, or in relation to, the Research Project that relates to, is based upon or arises as a result of use of,
the Sponsor Materials, Sponsor Confidential Information, and/or the Research Results.

 

1.4       "Project
Participant" means any employee, contractor or agent of Principal Investigator or Institution who may participate in the
Research Project, including, but not limited to, scientists, post-doctoral fellows, students, and technicians.

 

1.6       "Research
Parties" shall collectively refer to Institution and Principal Investigator.

 

 

 

    	 	22	 

     

    

 

1.7       "Research
Project" shall mean the Research Project conducted pursuant to one or more Work Orders to carry out the Purpose.

 

1.8       "Results"
shall mean any, and all data, information and results generated or produced in the performance of, or related to, the Research
Project by the Principal Investigator and Project Participants.

 

1.9       "Sponsor
Material" means any products, product candidates, compound, biomaterial or other substance of Sponsor delivered to Institution
and that may be used as part of the Research Project, together with its derivatives, progeny, parts, analogs and homologs, modifications,
and any other new chemical entity, developed by, or for, or otherwise obtained by Sponsor, including, but not limited to CAR-T
Technology.

 

1.20    "Work
Order" means any work order entered into by mutual agreement of the Parties to conduct the work for the Research Project,
with the understanding that Sponsor shall be under no obligation to enter into any particular Work Order or to advance funds for
any specific research or activities under the Research Project other than pursuant to a signed Work Order.

 

ARTICLE 2: RESEARCH PROJECT

 

2.1       General.
Institution, under the direction and supervision of the Principal Investigator, shall perform the Research Project in accordance
with (a) the one or more Work Orders entered into by the Parties, (b) the terms and conditions of this Agreement, (c) all instuctions
relating to the storage of Sponsor Material, and (d) all applicable international, federal, state and local laws, rules, regulations
as well as other requirements of any applicable governmental authority in the performance of the Research Project. Institution
shall proceed diligently with the work set forth in the Research Project by using its good faith efforts to allocate sufficient
time, effort, equipment and facilities for the conduct of the activities thereunder and using Project Participants with sufficient
skills and experience as are required to accomplish the objectives of the research activities set forth in the Research Project.

 

2.2       Participants.
The Research Project shall be conducted solely by Principal Investigator and Project Participants at the Institution. In the
event that the Principal Investigator becomes unable or unwilling to continue the Research Project at the Institution, Sponsor
shall have the option to: (a) continue the Research Project with a substitute researcher proposed by the Institution and approved
by the Sponsor (who shall thereafter be deemed to be the Principal Investigator for purposes of this Agreement); or (b) to terminate
this Agreement pursuant to Section 5.3.

 

2.3       Records. Institution and
Principal Investigator and all Project Participants shall keep and maintain accurate scientific records fully and properly
that reflect all work done and Research Results achieved in the performance of the Research Project and shall make such
records, including, without limitation, all records related to the Research Project and Research Results available to Sponsor
to audit and inspect following reasonable notification requesting an audit. It is understood that such records shall include
laboratory notebooks sufficient to document any patentable inventions developed, conceived or reduced to practice during the
course of the Research Project. Upon request by Sponsor and at Sponsor's expense, Principal Investigator shall within a
reasonable period of time provide copies of all such records to Sponsor. Such records shall be maintained by Institution
during the term of this Agreement and for three (3) years thereafter or such time as required by applicable laws, rules and
regulations, with the understanding that if Sponsor desires that the Institution maintain the records beyond the three (3)
years or such additional time as required, to the extent Institution agrees to such additional time, Sponsor shall be
responsible for the cost to maintain the records.

 

2.4       Funding.
As consideration for conducting the Research Project, Sponsor shall make available for the Institution the sums set forth
in the Budget for each Research Project. If the Research Project is terminated prematurely, the amount due hereunder shall be
an amount equal to the pro-rata portion of the actual work performed and reimbursement for any costs actually incurred by Institution
prior to termination.

 

 

 

    	 	23	 

     

    

 

If Sponsor requests, and Institution agrees,
to make changes to the scope of the Research Project and/or it becomes apparant that to carry out the Research Project revisions
will be required as to the amount of the Institution (FTEs or consumables) resources necessary to carry out the Research Project,
Institution shall provide Sponsor with a revised Indicative Budget, which shall be reflected in subsequent invoices from Institution
and payments by Sponsor pursuant to the terms of the revised Indicative Budget.

 

2.5       Financial
Reporting. Institutionand Principal Investigator acknowledge that Sponsor may be required by law or trade association rules
of which Sponsor is a member, related to the collection and reporting of any payments or transfers of value to certain healthcare
providers and teaching hospitals (collectively, "Financial Transparency Laws") , including, but not limited to, the
U.S. Physician Payment Sunshine Act, 42 U.S.C. § 1320a-7h, and the regulations implemented thereunder, to disclose to certain
government agencies or other entities payments made to the Research Parties or Project Participants under this Agreement. Institution
and Principal Investigator hereby consent to Sponsor's disclosure of such information, and acknowledge that such information may
become available to the public. Institution and Principal Investigator shall cooperate with Sponsor in its compliance with Financial
Transparency Laws in connection with this Agreement. Institution shall promptly provide Sponsor, in the format Sponsor requests,
with all information that Sponsor believes it needs to comply with Financial Transparency Laws in connection with this Agreement.

 

2.6       Reports.
Within twenty (20) business days following the end of each calendar quarter, the Party conducing the Research Project shall provide
a comprehensive summary of the findings, results, data and other information that are generated by the Research parties as a result
of the Research (the "Results") to Sponsor. During conduct of the Research Project, Institution will inform Sponsor
promptly of any unexpected events or results that arise related to the Sponsor Materials, including, but not limited to any toxicity
issues identified. Sponsor shall own the Results that are generated. Only Sponsor shall have the right to use the Results consistent
with the terms of this Agreement. Sponsor may use the final report and all Results in any manner deemed appropriate by Sponsor
for any purpose without further obligation or liability to the Institution including, without limitation, for further research
and development activities, as well as for submissions to the FDA, EMA or other regulatory authorities. For the avoidance of doubt,
the Institution and Principal Investigator shall not be permitted to use the Results for any purpose or third party research or
study without the prior written approval of the Sponsor.

 

2.7       Regulatory
Requests. After the completion of the Research Project, the Research Parties shall provide any information and assistance
reasonably requested by Sponsor for any regulatory filing or regulatory compliance activities relating to the Research Project
including any request for information from a regulatory agency. The Research Parties agree that time is of the essence with regard
to these matters and will take all steps necessary to respond to Sponsor in a timely manner.

 

ARTICLE 3: INTELLECTUAL PROPERTY RIGHTS

 

3.1       Ownership;
Limited License. The Research Parties acknowledges that the Sponsor Materials are, and shall at all times remain, the sole
property of Sponsor. Sponsor hereby grants to the Research Parties, during the term of this Agreement, effective upon delivery
of the Sponsor Materials to the Principal Investigator, a nontransferable, non-exclusive license, with no right of sublicense,
to use the Materials solely for performance of the Research under the terms of this Agreement.

 

3.2       Invention
Disclosure. Institution shall promptly and fully disclose to Sponsor in writing and with detailed specificity any Invention
related to the Research Project that is developed, conceived and/or reduced to practice by a Research Party or Project Participant,
within twenty (20) days of Institution becoming aware any such Invention ("Invention Disclosure"). Each Invention Disclosure
provided under the preceding sentence will include a description of the Inventions and a reference to this Agreement. All Invention
Disclosures shall be the Confidential Information of Sponsor. Sponsor shall solely own all Inventions, including those set forth
in an Invention Disclosure pursuant to this Section 3.2.

 

3.3       Raw
Data and Results. Institution and Sponsor appreciate and understand that through the work of Institution in conducting the
research plan, certain raw data and results shall be generated, which shall constitute Sponsor Confidential Information and relate
to, use or incorporate or are generated from Sponsor's information, documents, work product and any other Sponsor Materials that
are delivered by Sponsor to Institution to be evaluated by Sponsor as set forth in the research plan. The Institution and Sponsor
agree that such raw data and results shall be owned solely by the Sponsor.

 

 

 

    	 	24	 

     

    

 

3.4       Deliverables.
Sponsor is, and shall be, the sole and exclusive owner of all right, title and interest to all information, documents, work
product and any other materials that are delivered by Institution to Sponsor hereunder or identified in a Work Order and incorporated
by reference, or any other written document describing research or services to be performed by the Principal Investigator under
the terms of this Agreement ("Deliverables"), including all intellectual property rights therein.

 

3.5       Exclusive
Rights to All Inventions and Results. The Research Parties agree that all Inventions created by and through the Research Project
under this Agreement and all Results are solely owned by Sponsor and Institution has no rights, other than those Sponsor may grant
to Institution to such Inventions and Results.

 

3.6       No
Other Licenses. Except as expressly set forth in this Section 3, no other right, title or interest of any nature whatsoever
is granted by either Party to the other Party under this Agreement, and neither the delivery of Material nor the disclosure of
Confidential Information shall be deemed to grant any rights or license to Institution except for the limited license to use the
Materials in Research during the term of this Agreement, as expressly set forth in Section 3.1.

 

3.7       No
Third Party Rights. Neither Institution nor Principal Investigator has entered into any agreements with any third party providing
material or funding for the Research Project that could result in a claim by such third party that it has commercial rights to
any Inventions made by Institution under this Agreement. Institution will not involve any third party in the Research Project,
nor use material provided by a third party commercial entity in the Research Project, without first (a) providing to Institution
a copy of the proposed agreement governing Institution's obligations to such third party regarding the Research Project and (b)
obtaining Sponsor's written consent to such third party's involvement in the Research Project, such consent to not be unreasonably
withheld.

 

3.8       Protection
of Inventions. Sponsor at its sole discretion shall have the sole right to file for protection of any Inventions, including
through patent protection. To the extent that Sponsor files for a patent, Institution shall cause all Institution inventors of
an Invention to cooperate with Sponsor to provide assistance and execute any documentation necessary to perfect assignment. Sponsor
shall have all rights and final decisions as to the filing, prosecution and/or maintenance of all patents or patent applications
covering an Invention. Institution will and shall cause all Institution inventors and others who are necessary to cooperate with
Sponsor in any such filing, prosecution or maintenance.

 

ARTICLE 4: CONFIDENTIALITY

 

4.1       Confidential
Information. For purposes of this Agreement, the term "Confidential Information" means (a) all
information of a confidential, secret, and/or proprietary nature provided by or on behalf of on party or any of its
Affiliates to the other party in connection with this Agreement, designated as "confidential." Confidential
Information may include, without limitation: trade secrets; know-how; inventions; technical data; results specifications;
protocols; procedures; information related to chemical or biological compounds, including but not limited to information on
structure and activity; testing methods; business or financial information; information related to products, product
candidates or research and development programs; the results of research and development activities, including but not
limited to clinical trial results; product and marketing plans; customer and supplier information; and all information,
reports, evaluations and copies generated or derived by either Party from any of the foregoing. Confidential Information may
also include information obtained from collaborators, customers, suppliers or vendors of Sponsor or any of its Affiliates or
other third parties who have entrusted their confidential information to Sponsor or such Affiliates.

 

4.2       Restrictions on Disclosure and Use.
The Party receiving Confidential Information agrees that it will maintain all Confidential Information in strict confidence,
and shall disclose Confidential Information only to those employees, officers, directors and other representatives of the receiving
Party who are obligated to maintain the confidential nature of such Confidential Information and who have a need to know such
Confidential Information in connection with performance of the Research. Institution will not disclose Confidential Information
to any other person or entity without the prior written consent of Sponsor. The receiving Party will not use Confidential Information
except for purposes of performing the Research. Notwithstanding anything to the contrary in this Agreement, the receiving Party
shall be entitled to disclose Confidential Information to the extent required by applicable law or court order, provided that
the receiving Party furnishes the disclosing Party with prompt written notice that the Confidential Information is required to
be disclosed. Such notice must be given sufficiently in advance of the required disclosure so as to provide to the disclosing
Party with a reasonable opportunity to seek to prevent disclosure or to obtain a protective order for the Confidential Information.
The Parties will consult with each other prior to the receiving Party making any such required disclosure.

 

 

 

    	 	25	 

     

    

 

4.3       Exceptions. The obligations of
non-disclosure and non-use under this Agreement will not apply to information which the receiving Party can clearly demonstrate,
by written records, falls within any of the following categories:

 

(a)             
information that was generally known to the public prior to disclosure or being generated under this Agreement or later
becomes generally known to the public through no fault of the receiving Party;

 

(b)            
information that was already known to the receiving Party prior to disclosure or being generated under this Agreement;

 

(c)             
information obtained by the receiving Party from a third party other than on behalf of the disclosing Party and provided
such third party is lawfully in possession of and has the right to disclose the same without limitation upon further disclosure;
and

 

(d)            
information that was independently developed by the receiving Party without reference to the Confidential Information and
other than as part of the Research.

 

4.4       Safekeeping.
Institution shall maintain all the Materials and other Confidential Information disclosed to it in a secure place with access
limited to those persons who are specifically authorized to have access to such Confidential Information pursuant to this Agreement.
Institution shall promptly notify Sponsor of any unauthorized use or disclosure of Materials or other Confidential Information
of which it becomes aware or has knowledge and will take all reasonable steps to assist Sponsor in attempting to minimize any
potential or actual damages or losses resulting from such unauthorized use or disclosure.

 

4.5       Return
of Materials and other Confidential Information. Within thirty (30) days following the termination or expiration of this Agreement,
Institution shall, as directed by Sponsor, return to Sponsor or destroy any remaining Materials, including Sponsor Materials and
all other Confidential Information, including all reproductions and copies thereof, and shall delete all references to such Confidential
Information stored electronically or otherwise. At such time, Institution shall also notify Sponsor in writing as to how much
Material, including Sponsor was used in connection with the Research Project and how much Material was returned or destroyed under
the preceding sentence.

 

4.6       Injunctive
Relief. The receiving Party acknowledges and agrees that any violation of the terms of this Agreement relating to the disclosure
or use of Confidential Information may result in irreparable injury and damage to the disclosing Party not adequately compensable
in money damages, and for which the disclosing Party may have no adequate remedy at law. The receiving Party acknowledges and
agrees that, if the disclosure or use restrictions contained in this Agreement are violated, the disclosing Party may need to
obtain injunctions, orders, or decrees in order to protect Confidential Information and will be entitled to do so, in addition
to any other remedies available for breach at law or in equity, without having to post a bond or show harm.

 

4.7       Publication.
Institution may only publish or otherwise publicly disclose the Research Results with the prior written approval from Sponsor,
wherein such written approval shall not be unreasonably withheld.

 

4.3       Publicity.
No Party will use the name of another, nor of any of its employees, agents or representatives, in any promotion or advertising
without the prior written approval of an authorized representative of the other Party. The Parties may, however, acknowledge Sponsor's
support, the existence of this Agreement and the general nature of the research being pursued hereunder for such purposes as Sponsor
may consider appropriate or as required by law. In any such statement, the relationship of the Parties hereunder shall be accurately
and appropriately described.

 

 

 

    	 	26	 

     

    

 

ARTICLE 5: TERM AND TERMINATION

 

5.1       Term. The term of this Agreement shall
commence upon the Effective Date and continue in full force and effect until the earlier of a) completion of the Research Project
and b) July 31, 2020, unless terminated prior to such date in accordance with this Article 5.

 

5.2       Termination for Breach. Either Party
may terminate this Agreement, effective immediately, if the other Party materially breaches any provision of this Agreement and
fail(s) to remedy such breach within thirty (30) days after receipt of notice in writing of such breach from the other Party.

 

5.3       Sponsor Termination. If Principal Investigator
is unable or unwilling to continue to conduct the research or otherwise perform the obligations under this Agreement in connection
with the Research Project, or if Principal Investigator fails to use reasonably diligent efforts to conduct the Research Project,
Sponsor may terminate this Agreement upon thirty (30) days prior written notice to Institution and shall be under no further obligation
to make monetary payments to the Parties under this Agreement.

 

5.4       Effect of Termination and Expiration. Upon
expiration or any termination of this Agreement, (i) the Principal Investigator shall finalize the Results that have been compiled
to such date, and shall prepare and submit a final report with respect to such Results to Sponsor; and (ii) the Institution shall
return to Sponsor all unused Sponsor Materials and any Sponsor Confidential Information within twenty (20) days of Sponsor's request.
In the event of Sponsor termination, any funds paid to Institution by Sponsor under this Agreement which have not been expended
or irrevocably committed upon the effective date of termination shall be refunded to Sponsor within twenty (20) days after the
effective date of termination.

 

5.5       Survival. The following sections of
this Agreement shall survive expiration or any termination of this Agreement: Articles 3, 4, 6, 7 and 8 and Sections 2.3, 2.5-2.7,
5.4 and 5.5.

 

ARTICLE 6: REPRESENTATIONS, WARRANTIES
AND COVENANTS

 

6.1       Representations
and Warranties of the Research Parties. The Institution represents and warrants to Sponsor that:

 

(a)        
The execution, delivery and performance of this Agreement does not and will not conflict with or result in breach of any
term, condition, obligation or restriction of any other agreement with any third party;

 

(b)        
Principal Investigator's and Institution's participation in the Research Project and execution hereof, including the assignment
of Inventions and Deliverables to Sponsor set forth in Sections 2 and 3, shall not conflict with any obligations of Principal Investigator
to Institution or ally obligation of the Institution to any other person or entity;

 

6.2       Debarment.
Institution and Principal Investigator represent and warrant that neither they nor any Project Participant or any other person
retained to perform the Research Project pursuant to this Agreement, (a) is under investigation by the FDA for a debarment action
or is presently debarred pursuant to the Generic Drug Enforcement Act of 1992, as amended (21 U.S.C. §301 et seq.), (b) is
under investigation by the FDA for debarment action or is presently debarred pursuant to Section 306(a) or (b) of the Federal Food,
Drug and Cosmetic Act (21 U.S.C. 335a (a) or (b)), (c) has a disqualification hearing pending or has been disqualified by the FDA
pursuant to 21 C.F.R. Section 312.70 or its successor provisions, or (d) has been convicted of, or is currently charged with, a
felony for conduct relating to the regulation or handing of any drug product. In addition, Institution and Principal Investigator
represents and warrants to Sponsor that neither they nor any Project Participant or any other person retained to perform the Research
Project pursuant to this Agreement has engaged in any conduct or activity which could lead to any of the above mentioned disqualification,
debarment, felony or other actions. If during the term of this Agreement Institution, Principal Investigator or any Project Participants
or any other person retained to perform the Research Project pursuant to this Agreement: (w) comes under investigation by FDA for
a debarment action or disqualification, (x) is debarred or disqualified, (y) is convicted of, or is currently charged with, a felony
for conduct relating to the regulation or handing of any drug product or (z) engages in any conduct or activity which could lead
to any of the above mentioned disqualification or debarment actions, Institution and Principal Investigator shall promptly, but
in no case later than five (5) days, notify Sponsor.

 

 

 

    	 	27	 

     

    

 

6.3       NO
WARRANTY; DISCLAIMER. INSTITUTION ACKNOWLEDGES AND AGREES THAT THE MATERIALS ARE EXPERIMENTAL IN NATURE AND PROVIDED TO INSTITUTION
"AS IS." SPONSOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND WHATSOEVER, EXPRESSED OR IMPLIED, WITH
RESPECT TO THE MATERIALS. IN PARTICULAR, SPONSOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND WITH RESPECT TO
THE PURITY, TOXICITY, STABILITY, MERCHANTABILITY, TITLE, NON-INFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS.
ACCORDINGLY, SPONSOR SHALL NOT BE LIABLE FOR ANY CLAIMS INSTITUTION MAY HAVE AGAINST SPONSOR FOR ANY DAMAGES ARISING OUT OF INSTITUTION'S
HANDLING, USE, STORAGE AND DISPOSAL OF THE MATERIALS, EXCEPT TO THE EXTENT THAT SAID DAMAGES RESULT FROM THE GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT OF SPONSOR. SPONSOR DOES NOT ENCOURAGE VIOLATION OF ANY THIRD PARTY'S INTELLECTUAL PROPERTY RIGHTS.

 

6.4.      Sponsor
Indemnification of Principal Investigator and Institution. Sponsor will indemnify and hold harmless Principal Investigator,
Institution and their Affiliates and each of their respective directors, officers, agents and employees from and against any damages,
judgments, liabilities, penalties, losses, costs, and expenses, including, but not limited to, reasonable attorney's fees, (collectively,
the "Losses") incurred in connection with any third party claim arising out of any adverse event caused or resulting
from an issue with the Sponsor Materials itself that has been provided to the Institution by Sponsor or breach of any term of
this Agreement, except insofar as such Losses result from Institution's gross negligence or willful misconduct. Institution shall
notify Sponsor promptly of Institution's receipt of notice of any claim, proceeding or investigation for which indemnification
may be sought. Notwithstanding the foregoing, the failure to give notice shall not impact Institution right to indemnity under
this Section unless Sponsor has been prejudiced by such failure. Sponsor shall have the right, but not the obligation, to control
the defense of any claim for which Institution is seeking indemnification, provided Sponsor will not settle any such claim without
Institution prior written consent unless such settlement fully releases Institution without any admission of fault or wrong-doing
on Institution part. The indemnification set forth in this Section shall include amounts paid in settlement; provided, however,
that no such settlement shall be entered into by Institution without Sponsor's consent.

 

6.5       Institution Indemnification of Sponsor.
Institution will indemnify and hold harmless Sponsor and its Affiliates and each of their respective directors, officers,
agents and employees from and against any damages, judgments, liabilities, penalties, losses, costs, and expenses, including,
but not limited to, reasonable attorney's fees, (collectively, the "Losses") incurred in connection with any
third party claim arising out of any misuse of the Sponsor Materials by Institution the Principal Investigator or any employee
or other individual acting on behalf of the Institution and/or Principal Investigator or breach of any term of this Agreement,
except insofar as such Losses result from Sponsor's gross negligence or willful misconduct. Sponsor shall notify Institution promptly
of Sponsor's receipt of notice of any claim, proceeding or investigation for which indemnification may be sought. Notwithstanding
the foregoing, the failure to give notice shall not impact Sponsor's right to indemnity under this Section unless Institution
has been prejudiced by such failure. Sponsor shall have the right, but not the obligation, to control the defense of any claim
for which Sponsor is seeking indemnification, provided Sponsor will not settle any such claim without Institution's prior written
consent unless such settlement fully releases Institution without any admission of fault or wrong-doing on Institution's part.

 

6.6       Representations
and Warranties of Sponsor. Sponsor represents and warrants that Sponsor has the legal right, authority and power to enter
into this Agreement.

 

6.7       Payments. The Parties agree and acknowledge
that the compensation contemplated under the terms of this Agreement (a) constitutes fair market value for the Research Project.
The Research Parties represent and warrant that the Research Project accurately specifies the research to be provided by the Research
Parties; the Research Project performed under the Agreement does not involve the counseling or promotion of a business arrangement
or other activity that violates any law, rule or regulation; and the work specified under the Research Project does not exceed
what is reasonably necessary to accomplish its purpose.

 

6.8       AAALAC. If the Research Project includes
work that involves animal research, Institution each represent and warrant that, before commencement of activities under the Research
Project, it will either attain AAALAC accreditation or obtain Sponsor's written approval of the applicable procedures and standards
to be used in connection with the Research Project. Institution shall use its best efforts to maintain AAALAC accreditation (if
applicable) for the duration of the Research Project and shall notify Sponsor promptly if Institution loses such accreditation
during the Research Project, and provide with any such notice an explanation in reasonable detail describing the circumstances
surrounding the loss of such accreditation. The Research Parties agree to comply with AAALAC standards or such other standards
approved by Sponsor in writing, as the case may be, in respect of all activities conducted under the Research Project.

 

 

 

    	 	28	 

     

    

 

6.9       Export Control Laws. Institution agrees
not to export or re-export any Materials or Confidential Information unless Institution has obtained in advance all required licenses,
agreements or other authorizations from the U.S. and Russian Governments. No information or Materials provided to Institution
under this Agreement shall be exported, re-exported, transferred, or disclosed contrary to the applicable laws and regulations
of the United States and Russia, or to any country, entity or party which is ineligible to receive such information or materials
under United States and Russian laws and regulations, including the U.S. Department of Commerce and the U.S. Department of Treasury
and their Russian counterparts. Exports include, without limitation, the sending or taking of products, materials, items or technical
data out of the United States or Russia in any manner, disclosing or transferring technical data to a foreign person (i.e.,
any person who is not a lawful permanent resident of the U.S. or is not a protected individual as defined by 8 U.S.0 sections
1101 and 1324) whether in the United States or abroad, or performing services for a foreign client, whether in the United States
or abroad.

 

6.10    Limitations.
EXCEPT AS EXPRESSLY PROVIDED IN THIS ARTICLE 6, NO PARTY TO THIS AGREEMENT MAKES ANY WARRANTY, EXPRESS OR IMPLIED, EITHER IN
FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, RELATING TO THE RESEARCH PROJECT OR OTHERWISE UNDER THIS AGREEMENT, AND EACH
PARTY TO THIS AGREEMENT SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT OR WARRANTY OF
FITNESS FOR A PARTICULAR PURPOSE. SOME JURISDICTIONS DO NOT ALLOW LIMITATIONS ON IMPLIED WARRANTIES, SO THE ABOVE LIMITATIONS MAY
NOT APPLY TO A PARTY IN SUCH JURISDICTIONS.

 

ARTICLE 7: MATERIAL TRANSFER

 

7.1       Transfer. From time to time, Sponsor
will use reasonable efforts to deliver to Principal Investigator such quantity of Sponsor Material (or portion thereof) as needed
to conduct the Research Project. All Sponsor Material, and all title, interests, and rights therein, shall remain the sole property
of Sponsor.

 

7.2       Use
of Material. The Research Parties shall, and shall ensure that Project Participants, use the Sponsor Material solely in the
conduct of the Research Project and for no other purpose. The Research Parties shall not, and shall ensure that Project Participants
do not, use any Material for their own or others' benefit or for any purpose not exc 1 usively related to the Research Project,
including without limitation for any direct or indirect commercial purpose or for research, testing, diagnosis or treatment involving
human subjects, and shall not disclose, distribute, sell or otherwise transfer the Sponsor Material to any other commercial or
non-commercial third party without Sponsor's prior written consent. The Research Parties agree not to make any modifications of
any Sponsor Material, and agree that any invention or discovery made in violation of the foregoing shall vest automatically and
exclusively in the Sponsor. The Research Parties agree not to sequence, analyze or otherwise determine the chemical structure
or physical properties of any Sponsor Material, unless specifically agreed to by the Sponsor and contemplated by the Research
Project.

 

7.3       Storage
& Handling. All Sponsor Material shall be stored in a restricted area and handled, used and disposed of in accordance
with all applicable federal, state and local laws, rules and regulations. Upon conclusion of the Research Project or upon request
by Sponsor, the Principal Investigator and Institution shall discontinue use of all Sponsor Material and will arrange, at Sponsor's
option, for the return to Sponsor or for the lawful disposal of all unused Sponsor Material (and shall provide written certification
of same).

 

ARTICLE 8: GENERAL PROVISIONS

 

8.1       Independent Contractors. The relationship
of Sponsor, on the one hand, and Principal Investigator and Institution, on the other hand, established by this Agreement is that
of independent contractors, and nothing contained in this Agreement shall be construed to give either Party hereto the power to
direct or control the day-to-day activities of the other Party hereto, or constitute the Parties as partners, joint ventures,
co-owners or otherwise as participants in a joint or common undertaking. The Parties agree that neither the Principal Investigator,
nor any Project Participants is an employee of Sponsor.

 

 

 

    	 	29	 

     

    

 

8.2       Assignment. This Agreement
shall be binding upon and inure to the benefit of the Parties hereto, their respective successors, assigns, legal
representatives and heirs. Sponsor may assign or transfer Sponsor's rights and obligations under this Agreement to an
Affiliate or a successor to all or substantially all of Sponsor's assets or business relating to this Agreement, whether by
sale, merger, operation of law or otherwise, upon written notice to Institution. This Agreement shall not otherwise be
assignable by Institution without the prior written consent of Sponsor and any such assignment which does not receive such
prior consent shall be void.

 

8.3       Entire
Agreement. This Agreement constitutes the entire and only agreement between the Parties relating to the subject matter hereof,
and all prior negotiations, representations, agreements and understandings relating to the subject matter hereof are superseded
hereby, provided that Research Parties agree and acknowledge that Sponsor may enter into consulting type arrangements with certain
individuals at the Institution relating to the Research Project.

 

8.4       Notices.
All notices required or permitted under this Agreement will be in writing and will be given by addressing the same to the
address or fax number for the Sponsor or Institution set forth on the signature page of this Agreement or at such other address
or fax number as the Sponsor or Institution may specify in writing under this procedure. Notices will be deemed to have been given
(a) three (3) business days after deposit in the U.S. mail with proper postage for first class registered or certified mail prepaid,
return receipt requested; (b) one (1) business day after fax transmission, with receipt of transmission confirmed in writing and
confirmation copy sent by mail; or (c) one (1) business day after sending by a nationally recognized courier service for next
day delivery.

 

8.5       Modification.
This Agreement may not be modified except by a written agreement signed by each of the Parties hereto.

 

8.6       Waiver.
No waiver of any rights shall be effective unless agreed to in writing by the Party waiving such right, and the waiver of
any breach or default shall not constitute a waiver of any other right hereunder or any subsequent breach or default.

 

8.7       Subcontracting.
Institution shall not subcontract or otherwise engage or consult with any other person or entity, other than Principal Investigator,
to perform any of the Research Project without the advance written consent of Sponsor,which written consent shall not be unreasonably
withheld or delayed. Notwithstanding the foregoing, Institution may subcontract with the Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Russian Academy of Sciences for all or part of the work to be performed hereunder.

 

8.7.1    Permitted
Subcontractor. Sponsor's written approval of any subcontractor ("Permitted Subcontractor") shall not relieve the
Principal Investigator or the Institution of its obligations under the Agreement, and the Principal Investigator and Institution
shall remain fully responsible for ensuring the performance of each such Permitted Subcontractor and its employees and for their
compliance with the relevant provisions of the Agreement including but not limited to intellectual property, confidentiality, and
publication provisions;

 

(a)         
The Principal Investigator and Institution each represents and warrants that the Permitted Subcontractor shall perform its
obligations hereunder in accordance with the Law, the terms of this Agreement and any Research Project issued hereunder; and

 

(b)        
Require each Permitted Subcontractor to be bound in writing by clauses substantially similar to the confidentiality provisions
herein and require each Permitted Subcontractor to assign intellectual property assignment or license provisions of this Agreement
to Sponsor, unless Sponsor agrees otherwise in writing.

 

(c)        
Each of the Principal Investigator and Institution is responsible for all Institution Permitted Subcontractor(s) and for
the payment of their compensation, including, if applicable, withholding of income taxes, and the payment and withholding of social
security and other payroll taxes, unemployment insurance, workers' compensation insurance payments and disability benefits.

 

8.8       Headings. The headings of the Articles
and sections of this Agreement are intended for convenience of reference only and are not intended to be a part of, or to affect
the meaning or interpretation of, this Agreement.

 

 

 

    	 	30	 

     

    

 

8.9       Severability. if, under applicable
law or regulation, ally provision of this Agreement is invalid or unenforceable, or otherwise directly or indirectly affects the
validity of any other material provision(s) of this Agreement ("Severed Clause"), it is mutually agreed that this Agreement
shall endure except for the Severed Clause. The Parties shall consult and use their best efforts to agree upon a valid and enforceable
provision which shall be a reasonable substitute for such Severed Clause in light of the intent of this Agreement.

 

8.10     Construction. The Parties
agree that they have participated equally in the drafting of this Agreement and that the language herein contained should not
be presumptively construed against any of them.

 

8. 11   Counterparts. This Agreement
may be executed in any number of counterparts, each of which will be deemed to be an original and all of which together will constitute
one and the same instrument. Signature pages to this Agreement may be exchanged electronically as a portable document format (.pdf)
file and such signature pages shall be deemed originals.

 

8.12     Choice
of Law and Venue. This Agreement shall be governed by and construed in accordance with the laws of the United States.
Further, the Parties irrevocably agree that any legal action or proceedings brought by or against them with respect to this Agreement
shall be brought in the courts of the United States, and ill particular, the Federal and State Courts of the State of Massachussets
and, by execution and delivery hereof, the Parties irrevocably submit to such jurisdiction and hereby irrevocably waive any and
all objections which they may have with respect to venue in any of the above courts.

 

 

 

 

 

 

 

 

 

[Signatures on following
page]

 

 

 

 

 

 

 

 

    	 	31	 

     

    

 

 

 

 

IN WITNESS WHEREOF, each
Party has executed this Agreement by a duly authorized individual effective as of the Effective Date.

 

	Xenetic Biosciences, Inc.	PJSC <<Pharmasynthez>>
	 	 
	 	 
	By: /s/ Jeffrey F. Eisenberg                          	By: /s/ Peter Kruglyakov                          
	 	 
	Name: Jeffrey F. Eisenberg                          	Name: Peter Kruglyakov                          
	 	 
	Title: CEO                                                  
      	Title: CEO                                                 
	 	 
	 	7/8/19

 

 

 

 

PRINCIPAL
INVESTIGATOR’S CERTIFICATION

 

I
acknowledge that I have read the foregoing Agreement. I will comply with the terms and conditions of the Agreement both as an
individual and as an employee or agent of Institution and I hereby certify that the representations and warranties by me as
the Principal Investigator in the Agreement are true and correct on the date hereof.

 

Principal Investigator

 

 

/s/
Surkov Kirill                                                              

Signature

 

Name:
Surkov Kirill

 

Title ______________________________________

 

 

 

 

 

 

 

 

 

    	 	32

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00312-of-00352.parquet"}]]